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l)INNOVATION PARADOX IN VACCINE TARGET SELECTION
Public health is continually threatened by re-emerging and newly emerging infections,
as well as pathogen resistance to available intervention strategies. This persistent threat
challenges vaccine developers to anticipate future epidemiological outbreaks.
Nevertheless, there are insufficient resources available to address all unmet medical needs.
Furthermore, vaccine development is affected by the so-called innovation paradox,
significantly affecting vaccine valorization productivity. In the view that there is a
correlation between health and wealth; it is critical to select the appropriate target
disease area for vaccine development. 
This dissertation evaluates the innovation paradox in vaccine target selection. When it
comes to selecting the target; infectious diseases are manifested at the macro-level, for
which valorization solutions are pursued at the micro-levels. This micro- and macro-level
action-reaction dynamic lies at the heart of the innovation paradox. The six research
chapters offer an assessment into entrepreneurial and organizational micro-level
productivity, focusing on strategies that stimulate or restrict vaccine target selection.
Additionally, we propose the valorization process would be more efficient as an all-
inclusive cycle, delineating a number of sequential steps from bench-to-bedside and back
again. Such a cycle would allow for proper assessment into the available resources, in
order to most accurately determine and address the unmet medical need. 
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1.1  Health and Wealth 
 
Good health is an internationally recognized fundamental human right 1. Health is also an 
important economic engine 2. As published in Bloom’s Health and Wealth of Nations, the 
positive correlation between a nation’s wealth and an individual’s health status is best 
described as mutually reinforcing 3. Among the multiple challenges facing public health, 
infectious diseases are the second largest cause for mortality (Glossary 1.3.1). 
 
“Great pandemics and local epidemics alike have influenced the course of wars, 
determined the fates of nations and empires, and affected the progress of civilization, 
making infections compelling actors in the drama of human history.” 
 
Fauci and Morens (2012)4 
 
To date, prophylactic vaccines are considered the most effective/cost-effective strategy for 
mitigating the spread of infectious diseases, thereby maintaining public health (Glossary 
1.3.2 and 1.3.3) 5. In fact, the history of population mortality statistics reveals that a 
combination of improved sanitary conditions, access to potable water, antibiotics, 
antivirals and vaccines has lead to a greater control over infectious diseases  6. Vaccines 
have served the late-twentieth century population by eradicating smallpox, and 
significantly reducing the global incidence of various other infections, including; 
poliomyelitis, diphtheria, tetanus, pertussis, measles, mumps, rubella, heamophilus 
influenza type B, hepatitis A virus, hepatitis B virus and pneumococcal bacteria 6. 
Additionally in the veterinary field, appropriately directed vaccination campaigns against 
the rinderpest virus have lead to its eradication in 2011 7, 8. 
 
This incredible accomplishment has been enabled due to improvements in the accessibility 
of vaccines. Improving access to essential medicines is more than just a simple logistical 
equation between the supplier and customer. Access involves pharmaceutical, social, 
political and economic interests, essentially encompassing four key processes; architecture, 
availability, affordability and adoption 9-11. Here we will not discuss architecture and 
adoption. 
 
Starting with affordability: global vaccine coverage rates have been stimulated by various 
sustainable financing mechanisms. Such procedures mediate the financial aspects between 
the customer- (vaccine acquisition budgets of local governments) and the supplier-side 
(vaccine price as set by the manufacturer). These economic tools include the extended 
programme of immunization (EPI) and a tiered-pricing scheme 12-15. EPI is a programme 
set up by the World Health Organization (WHO) in 1974 in order to ensure that children 
all over the world have access to vaccines 16. Tiered pricing allows for the average price 
per vaccine unit to be adjusted according to a nation’s income level 17, 18. Both systems 
have been realized through collaboration between numerous public and private 
stakeholders, including; the WHO, United Nations Children’s Fund, Pan-American Health 
Organization, Global Alliance for Vaccines and Immunization, the Bill and Melinda Gates 
Foundation, the Vaccine Fund and various other (non-) governmental institutions 13, 16. 
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In terms of availability: although vaccine development was initially undertaken by 
governmental public-sector institutions, vaccine development today is dominated by 
private-sector commercial ventures 19, 20. The vaccine industry is currently led by five 
biopharmaceutical manufacturers, holding a combined market share of 85%A. 
Considerable advancements regarding (fundamental) knowledge on epidemiology, the 
immune system and vaccine and antiviral technologies drive innovation. As a result, the 
industry has successfully marketed paediatric and adult prophylactic vaccines covering 
over 25 infectious diseases 21. Moreover, the application of vaccines is expanding to 
include immunotherapeutic targets for both cancer and chronic auto-immune diseases 22, 23. 
 
In order to commercialize a vaccine, the candidate antigen has to complete the 
pharmaceutical value chain (PVC). The value chain describes the (inter)nationally 
regulated chronological stages an antigen candidate has to complete - starting from the 
discovery phase through to human clinical trials - before it can be commercially exploited 
on the market (Glossary 1.3.4) 24. As a candidate molecule successfully proceeds along the 
PVC phases, its value - as expressed in financial terms - increases. This process of value 
accumulation is also referred to as valorization (Glossary 1.3.5), and occurs mainly due to 
two reasons. First, the amount of resources required for developing the candidate molecule 
accumulates progressively with each consecutive phase. Second, with each successfully 
completed development phase the probability of regulatory approval for market entry rises. 
In other words; risk reduction of the financial investment is correlated with a higher 
value25. 
 
Nevertheless, vaccine development is threatened by the so-called innovation paradox. In 
short; regardless of increasing R&D activities, the predicted output - as measured by 
successful market entry of the product - is lacking 26. This situation has intensified over the 
past few decades and significantly affects the productivity of vaccine candidate 
valorization. Reasons include, but are not limited to; rising R&D costs, lower approval 
rates, vaccines competing with enhanced best standards of care, static patent timelines in 
combination with longer development timelines, an increasingly demanding regulatory 
environment and more stringent pricing and reimbursement criteria 27-29. 
 
Additionally, public health is continually challenged by re-emerging and newly emerging 
infections as well as pathogen resistance to available intervention strategies, including anti-
infectives and vaccines. Consequently, the persistent threat of the unmet medical need, 
want or demand challenges vaccine developers to anticipate future epidemiological 
outbreaks 6 (Glossary 1.3.6). Furthermore, in the view that certain infectious diseases are 
known as poverty-inducers, it is critical to select the appropriate target disease area for 
vaccine development 30. Only through continued innovation will the biopharmaceutical 
community be able to respond appropriately to the substantial burden of the infectious 
pathogen. An appropriate response combines a timely production of a safe and effective 
high quality vaccine, while ensuring wide-spread access for the (high riskB) population 
groups.  
                                                          
A The so-called ‘big-five’ consist of: Sanofi Aventis, GlaxoSmithKline, Merck, Pfizer and Novartis  
B High risk groups include children, elderly, and immunocompromised patients 
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Here we evaluate the impact of the innovation paradox on selecting human infectious 
disease targets for vaccine development. Due to the complex nature of the topic, it is 
approached using a multidisciplinary perspective, combining a wide-range of scientific 
disciplines including epidemiology, virology, bacteriology, immunology, economics, 
management and organization. Moreover, the research as presented in this dissertation 
focuses on the innovation paradox from the individual- and organizational-levels (Figure 
1.1). In essence, it is at these two levels that vaccine development takes place and where 
target infectious disease selection has direct consequences to the unmet medical wants, 
needs and demands at the societal-level. The aim is to keep vaccine valorization innovative 
and productive, for the benefit of public health. 
 
Figure 1.1 Defining Multi-level Analysis 
This dissertation focuses specifically on the individual-/ micro-level and organizational level 
regarding the innovation paradox in vaccine target selection. 
 
 
 
 
1.2 Outline  
 
The studies presented in this dissertation are organized according to the framework in 
Figure 1.2. The first section is a general introduction to entrepreneurial-/micro-level 
concepts of vaccine development. The second section concentrates on the organizational-
level productivity and dynamics. Section three reflects on all previous chapters, evaluating 
the impact of the organizational environment on entrepreneurial activity. The dissertation 
ends with a discussion, presenting the lessons learned regarding the effect of the 
innovation paradox on the valorization cycle, which in turn influences vaccine target 
selection.  
 
 
SOCIETAL-/ 
MACRO-LEVEL: 
Needs, Wants, 
Demands 
SECTOR LEVEL: 
Institutional and 
Biotechnology 
Infrastructure 
ORGANIZATIONAL 
LEVEL:  
Value Chain 
INDIVIDUAL -/ 
MICRO-LEVEL: 
Entrepreneur 
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Chapter 2 introduces entrepreneurial level concepts, focusing on the specific roles of 
scientists, inventors and entrepreneurs, and their contribution to the field of vaccine 
development. Although the chapter focuses on vaccine development, the average 
probability of success and milestone investment per phase is contrasted with that of drug 
development. Ultimately we attempt to answer the question; which entrepreneurial role 
would be most effective in order to advance, promote, and commercialize prophylactic 
treatments against infectious diseases? Through applying entrepreneurial theories on 
science-based venturing, the innovative capacities of the various entrepreneurial roles 
contributing to the value chain are evaluated.  
 
Chapters 3 and 4 define markers of organizational-level productivity for vaccine 
development. Chapter 3 reviews the gold pharmaceutical industry standards for the 
success rates and associated costs of new chemical entity (NCE) development. Although a 
publication by Dimasi (2003) is widely quoted as the gold standard for describing the 
industries’ productivity, the literature survey resulted in an additional six publications on 
the same topic. We also introduce the link between productivity and risk profiles, and 
analyze the various calculating procedures with which to determine the productivity rate. 
 
Chapter 4 fine-tunes the calculation parameters and risk profiles for human vaccines in 
development. A risk profile combines phase duration with market entry probabilities, and 
is granulated based on target disease area. Furthermore, risk profile behaviour for chronic 
versus acute infectious diseases, and prophylactic or therapeutic vaccines is investigated. 
Ultimately we demonstrate that risk profiles are useful tools in calculating the productivity 
of the vaccine industry, and delineating the productivity gap. 
 
Both Chapter 5 and 6 focus on organizational-level dynamics, evaluating the factors 
directly influencing the development timelines of the vaccine value chain. Chapter 5 
evaluates the productivity of the administrative paper trail of a clinical phase I trial in an 
academic research organization (ARO). The focus lies on sponsor queries. Sponsor queries 
are officially recorded questions concerning potential discrepancies between the raw paper 
data and its’ electronic, manually entered copy. Current protocols require a 100% check of 
all data points using various mechanisms. Such quality checks are completed by ARO and 
the clinical trial sponsor as well as regular governmental and international audits. This 
study explores the error-rate of data management quality control mechanisms and 
delineates a novel quantitative approach for evaluating the productivity of clinical trial data 
management procedures. 
 
Chapter 6 offers an exploratory view on the potentially rate-limiting factors encountered 
during adjuvanted-vaccine development that affect value chain dynamics. Adjuvants are 
considered immunostimulating substances that can be added to a vaccine. Although 
adjuvants have the potential to elicit adverse reactions, they also offer certain benefits 
including; increasing the immune response in senescent population groups and dose-
sparing properties. Nevertheless, after approximately 90 years of R&D, we question why 
only four adjuvants have been approved for use in human vaccines? Although ample 
literature is available describing the main risks for developing adjuvanted-vaccine 
candidates, it remains unclear as to how these potentially rate-limiting factors compare and 
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interact. Key opinion leaders in the field of adjuvanted-vaccine development were 
approached in order to collect a unique qualitative empirical dataset.  
 
Chapter 7 reflects on the previous studies from an entrepreneurial-perspective. This 
chapter essentially reviews key ingredients learned from organizational-level productivity 
and dynamics, which have the potential to greatly enhance entrepreneurial activity. 
 
Figure 1.2 Organization of the research chapters  
 
Objective
Innovation Paradox in Vaccine
Target Selection
Productivity
Chapter 3 and 4
Summarizing Discussion
Valorisation Cycle
Chapter 8
Dynamics
Chapter 5 and 6
Section One
Entrepreneurial Concepts
Chapter 2
Section Three
Entrepreneurial
Reflection
Chapter 7
Section Two
Entrepreneurial
Level
Organizational
LevelSocietal/Macro
Level
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1.3 Glossary of Central Concepts 
 
1.3.1 Epidemiology 
 
Epidemiology is the study of the incidence, distribution/spread and control of diseases 31. 
When it comes to studying infections; communicable pathogens remain a leading major 
cause of mortality, disability and social and economic disorder, disproportionally affecting 
developing countries 32. Infectious diseases account for approximately a quarter of annual 
deaths worldwide (Figure 1.3). The majority of these 15 million live in low- to middle-
income countries 33-35.  
 
Figure 1.3 Global estimated annual causes of mortality 33 
 
 
 
The most common infectious diseases affecting the human population include respiratory 
infections, HIV/AIDS, diarrhoeal diseases, tuberculosis and malaria (Table 1.1) 33. If these 
statistics were to take disease latency into consideration, the number of individuals 
affected would be far more substantial. For example; over 31 million people are infected 
with HIV 36, at least 350 million individuals are carriers of Hepatitis B, and another 100 
million for Hepatitis C 37. Although vaccines are considered the best approach for all of the 
pathogens listed in Table 1, there are still multiple unmet medical needs (Glossary 1.3.6). 
 
One of the key features that distinguishes infectious diseases from other human diseases is 
the theoretical notion that infectious diseases can be eradicated 4. Eradication is defined as 
Cardiovascular 
Conditions 
29% 
Infectious 
Diseases 
26% 
Neoplastic 
Diseases 
13% 
Injuries 
9% 
Asthma and 
Chronic 
Obstructive 
Pulmonary 
Diseases 
5% 
Other 
18% 
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“Permanent reduction of the worldwide incidence of infection caused by a specific agent as 
a result of deliberate efforts, whereby intervention measures are no longer needed 38.” Even 
though global eradication programmes find significant financial, political and societal 
support39, they are considered a high risk, lengthy and resource intensive process. The 
availability of a vaccine is simply not sufficient. Other features should also be into 
account, including but not limited to; the biological features inherent to the pathogen and 
its replication life-cycle, technological factors, cost-benefit analysis of resources required, 
and surveillance infrastructures 38. Infectious disease candidates eligible for eradication in 
the near future - as identified by the Carter Centre International Task Force - includes 
poliomyelitis 40-42.  
 
Table 1.1 Global estimated annual mortality rates for infectious diseases, and availability 
of prophylactic vaccines 6. 
 
Infectious Disease Mortality Rate/ Millions 33 Example Vaccine Availability 
Respiratory 
Infections 3,96 Seasonal Influenza 
Yes; inc. adjuvanted 
vaccines 
HIV/AIDS 2,77 HIV/AIDS No 
Diarrhoeal 
Diseases 1,80 
Rotavirus Yes 
Enterotoxigenic Escherichia 
coli (ETEC) No 
Tuberculosis 1,56 Tuberculosis (TBC) Yes; limited long-term protection 
Malaria 1,27 Malaria No 
(Preventable) 
Childhood Diseases 1,12 
Heamophilus Influenzae 
Type B Yes 
Respiratory Syncytial Virus No; monoclonal antibody 
Sexually 
Transmitted 
Diseases 
0,18 Human Papilloma Virus Yes 
Meningitidis 0,17 Meningococcal Meningitidis Yes; not all strains 
Hepatitis B and C 0,16 
Hepatitis B Virus (HBV) Yes 
Hepatitis C Virus (HCV) No 
Tropical Parasitic 
Diseases; other 
than Malaria 
0,13 Leishmaniasis No 
Dengue 0,02 Dengue No 
Other; 
Newly emerging 
Infections 
1,76 
Japanese Encephalitis virus Yes 
Enterovirus 71 (EV71) No 
Anthrax Bioterrorism Yes; US military only 
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1.3.2 The Immune System and Vaccines 
 
The immune system is a complex bodily process that - under normal circumstances and in 
healthy state - actively eliminates infectious pathogens. An immune response is a 
coordinated event between innate and adaptive components of the immune system. This 
response aims to neutralize and clear the pathogen as efficiently as possible while attaining 
some form of immunological memory in case of future contact. Immunological memory 
can only be established through the adaptive immune system, which consists of two arms; 
the cell-mediated immunity and humoral antibody mediated immunity 43.  
 
Nevertheless, infectious pathogens are continuously evolving, persistently posing a threat 
to an individual’s health status. This evolutionary rate of change is driven by a 
combination of mutations in genetic material and natural selection processes 44. Such 
changes allow for the pathogen to adapt in order to infect other immunologically naïve 
species (Zoonosis is an example), and/or evade the host’s immune system 45. This 
evolutionary rate is also dependent on the antigenic variability of the pathogen. An 
example of a pathogen with low antigenic variability is the measles virus; one infection 
episode with the wild-type virus often leads to life-long immunological memory 46, 47. 
Examples of pathogens with higher antigenic variability include influenza virus (variability 
is seasonal) and HIV/AIDS (variability can be daily) 45.  
 
In the situation where the pathogen is highly infectious, has a high mutation rate, or if the 
immune system cannot perform optimally (e.g. in the very young, the elderly or 
immunocompromised patients), or a combination of all conditions: the infection can result 
in complications with sometimes fatal consequences. It is under these circumstances that 
the immune system can benefit from either passive or active immunization through 
administration of vaccines, antivirals and/or isolated immunoglobulins 43. 
 
Historians believe the origins of vaccinology most likely stems from the homeopathic 
beliefs that: “a small dose of an infectious disease could protect against severe disease 19.” 
Even as early as the 11th century Chinese documents describe immunization techniques 
against the smallpox virus: administering dried smallpox scabs from an infected individual 
to the naïve recipient via the skin or the nasal route 19, 48. It is believed this technique 
became available to the British in the early 18th century, from where the procedure spread 
to other parts of Europe and America 48. Nevertheless, popular biology books have adopted 
Edward Jenner’s Cowpox experiments in the 1790s as the initiator of the vaccinology 
discipline. Ultimately his research on the pox virus proves a vital cornerstone towards the 
global eradication of smallpox in 1977 6, 20, 49. Consequently, from the late 18th/early 19th 
century onwards; vaccine developers started designing vaccines for a range of human 
infectious diseases 6, 20.  
 
However, vaccination has its share of limitations, of which we present a few. First, 
virtually all successful vaccines used today are based on the induction of an adequate 
humoral immune response. Examples include paediatric Measles, Mumps and Rubella 
(MMR) and Diphtheria, Pertussis, Tetanus and Polio (DPTP) combination vaccines 6. 
Stimulating the other protective cell-mediated arm of the immune system has proven to be 
more challenging. Nevertheless, for some infectious agents a humoral response is simply 
 10 
not a sufficient correlate of protection 50, 51. Second, there are limits to the immunogenicity 
of administering the antigen. Solutions are sought in the direction of improving epitope 
identification, administration routes, adjuvants 52-55 and delivery vehicles (including pre-
loaded dendritic-cells, lipid carriers, and various viral-, plant- and bacterial-vectors) 
amongst others 56. As a final point, vaccination is associated with certain health risks 57. In 
some cases the adverse reactions (allegedly) caused by the vaccine, have resulted in the 
regulatory authorities removing that product from the market. Such a suspension can be 
permanent or temporary; in the latter case the product will be pending additional research. 
One recent example includes the temporary suspension (currently authorized again) H1N1 
pandemic influenza vaccine Pandemrix ® by the European competent authority, on 
account of alleged association with increased incidence rate of narcolepsy58. Nevertheless, 
in the view that prophylactic vaccines are generally administered to healthy individuals, 
the statistical likelihood of developing a side-effect is kept to the absolute minimum.  
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1.3.3 Vaccine Cost-Effectiveness 
 
Vaccines are considered to be the most cost-effective method in controlling the spread of 
communicable diseases 59. On the other hand, therapies for infectious diseases are not 
exclusive to vaccine developers. Although this fact is not highlighted within the 
dissertation, it is important to consider nonetheless; vaccines are in competition with NCE 
when it comes to developing therapies targeting infectious diseases. Examples of such 
diseases include HIV/AIDS and Malaria, for which therapies are designed by altruistic 
foundations, pharmaceutical companies and biotechnology firms.   
 
Vaccines are available in three varieties; prophylactic (prior to the infection), therapeutic 
(during disease manifestation), or post-exposure prophylactic (PEP). PEP is also known as 
secondary prophylaxis, whereby the vaccine is generally administered within a few hours 
after exposure to the pathogen. As elaborated in Chapter 4, the majority of available 
vaccines targeting infectious diseases are prophylactic. A smaller portion of available 
vaccines are therapeutic, and most often target cancer and auto-immune diseases. 
Therapeutic vaccines for the treatment of HIV/AIDS and Hepatitis C Virus (HCV) are 
currently in the development pipeline. Only a sub-section of available vaccines are 
considered PEP, and target diseases such as rabies, tetanus and Hepatitis B Virus (HBV).  
 
Nevertheless, vaccines are considered to provide more value for every invested dollar 
when compared to that same dollar invested in a new chemical entity 60-62. One reason is 
the fact that NCE largely focus on therapeutic applications, whereas vaccines are mostly 
prophylactic 63. Additionally, vaccines require a lower average investment and shorter 
development timelines when compared to the average drug in development (Chapter 2). 
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1.3.4 Pharmaceutical Value Chain 
 
The value chain is also referred to as the theory on safety and efficacy. Each development 
phase focuses on exploring and establishing safety and efficacy of the candidate entityA 
while maintaining specific qualitative and ethical standards 64, 65. It has evolved into its 
current format to reflect this theory, given specific fraudulent cases and medical 
disasters66,67. Such incidents have resulted in rethinking the ethics and procedures for 
human clinical trials, contributing to the establishment of the following; the Nuremburg 
Code in 1947 68, 69, the World Medical Association Declaration of Helsinki in 1964 70 and 
International Conference of Harmonization (ICH) Good Clinical Practice in 1996 71. 
 
The value chain starts off with the discovery phase. The target disease is selected, and the 
screening of potential candidate entity begins. In this selection process, hundreds of 
candidates are selected from thousands of entities based on preliminary efficacy data. In 
silico and in vitro methods dominate this stage, often resulting in a patent application. 
 
Following is the pre-clinical phase where the candidate entity is tested using in vivo animal 
models. In this phase, data on the efficacy and toxicity of the candidate is collected, to 
identify its potential for treatment in humans.  
 
Between animal testing and human clinical trials, the clinical trial sponsor compiles a 
dossier on the safety and efficacy data of the candidate entity. This file is submitted to the 
appropriate regulatory authority and ethical review board for assessment. The dossier has 
to be approved before advancement to the next PVC stage (Table 1.2). 
 
Table 1.2 Submitted documents required for the candidate molecule to advance from pre-
clinical to human clinical trials, per region 71, 72. 
 
Region Regulatory Agency Document Title 
United States (US) Food and Drug Administration (FDA) Investigational New Drug (IND) 
Europe (EU) European Medicines Agency (EMA) Clinical Trial Agreement (CTA) 
Japan 
The Ministry of Health, Labour and 
Welfare – Pharmaceuticals and Medical 
Devices Agency 
Clinical Trial Notification 
(CTN) 
Brazil Brazilian Health Ministry – Brazilian Health Surveillance Agency 
Comunicado Especial 
(Special Communication) 
Russia Ministry of Health and Social Development IND 
India 
Ministry of Health and Family Welfare - 
Central Drugs Standard Control 
Organization 
(Clinical Phase I trials not 
allowed) 
China State Food and Drug Administration Clinical Trial Application or Chinese IND 
 
                                                          
A Candidate entity in this description can be either a NCE or a vaccine antigen.  
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Clinical development is defined as; “research using human volunteers (also called 
participants) that is intended to add to medical knowledge 73”. A randomized, double-blind, 
(placebo) controlled human trial is the undisputed instrument for proving a candidate 
entity’s safety and efficacy, and consists of four sub-phases (Table 1.3). 
 
Table 1.3 Sub-phases of clinical development phase 73 
Pk/PD Pharmacokinetic/ Pharmacodynamic properties 
ADMET Acronym for drug administration, delivery, metabolism and excretion pathways and 
toxicology study 
 
Clinical 
sub-phase Aim Purpose 
Quantity 
Volunteers 
Average 
Length 
Phase I Exploratory 
First in human safety; 
Multiple dose; 
Pk/Pd and ADMET 
Healthy; 
20-100 
Several 
months 
Phase II a Exploratory 
Short-term safety; 
Dose tolerability; 
Proof of concept 
Patients; 
Several 
100 
Up to 2 years 
Phase II b Confirming 
Effectiveness of dose 
regimen; 
Drug delivery; 
Biological activity 
Patients; 
Several 
100 
Up to 2 years 
Phase III Confirming 
Safety; 
Dosage; 
Effectiveness; 
(often) Multi-centre 
Patients; 
+/- 1000 1 to 4 years 
Phase IV Post-Marketing 
Observational short-term and 
long-term side-effects Patients 
After market 
entry 
 
Prior to market entry and Clinical Phase IV, the sponsor submits another report to the 
regulatory authorities, for example the Common Technical Document (CTD) or the 
ASEANA CTD 72. The CTD is an initiative by the ICH, and aims at unifying the 
interpretations of the rules and regulations for medical drug and device development at a 
global level. This dossier describes the experimental results of the candidate entity, given 
superiority or non-inferiority for certain safety and efficacy parameters. Regulators 
examine the evidence, and decide whether the candidate meets all safety, efficacy and 
quality standards to allow market entry. Even after approval the entity is subjected to 
testing in the form of a phase IV post-marketing surveillance clinical trials. In this phase 
the short- and long-term side effects of the product in patients are monitored. This phase 
can last as long as the market life-cycle of the entity.  
  
                                                          
A ASEAN – Association of South-East Asian Nations 
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1.3.5 Valorization, Innovation, Productivity Gap and Innovation 
Paradox 
 
The concepts of valorization and innovation, as well as the productivity gap and the 
innovation paradox, are closely related and deserve further clarification in order to avoid 
confusion (Figure 1.4).  
 
In the case of vaccine development, both valorization and innovation pathways are laid-out 
by the pharmaceutical value chain. Valorization describes the processes of allocating a 
value toward an entity, and creating added value for its financial asset 74. This entity could 
take any shape or form, including but not limited to; product, process, service, technology 
and knowledge. The goal of valorization is to realize an added value for the transaction, as 
the entity is transferred from one development step to the next. Over the course of the 
value chain, valorization is the accumulation of value over the successfully completed 
phases. It is distinct from technology transfer processes, which (only) supervises the 
exchange of the entity between development phases.  
 
Innovation can also be viewed as adding value, whereby the end-result is a commercial 
entity 75. In this case, the new entity is essentially known as the invention, and the degree 
of novelty is assessed as either incremental or radical. Additionally, the value of an 
innovation is determined by market entry, for which the value is influenced by the 
dynamics of supply and demand 75. Therefore, the value of innovation is in absolute terms, 
encompassing all value chain procedures.  
 
The productivity gap describes the situation whereby the resources invested in the R&D 
process do not correlate with the anticipated output 76, 77. In the case of vaccine 
development, R&D procedures are synonymous to the various phases of the 
pharmaceutical value chain, and the output is a measure of successful market authorized 
vaccine products. 
 
The innovation paradox describes the situation whereby the number of novel 
entities/inventions do not correspond to the anticipated commercial market entries 78. This 
concept is separate from the knowledge paradox, which defines the complex relationship 
between the sharing of invention and the necessities for its protection through intellectual 
property strategies 79.  
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Figure 1.4 Valorization, innovation and technology transfer placed in context of the 
vaccine value chain  
 
Preclinical PhaseDiscovery Phase Clinical Phase I-III Post-Marketing SurveillanceIND CTD
Technology Transfer
Valorization
Innovation
Value
Vaccine Value Chain
Invention Innovation
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1.3.6 Unmet Needs, Wants and Demands 
 
When describing the innovation paradox in vaccine target selection, it is important to 
understand the differences between the (un-) met medical need, want and demand. In the 
view that these terms often imply different connotations for the various scientific 
disciplines, they deserve further clarification. 
 
A need describes the fundamentals required to sustain a healthy individual. This term is 
generally used by medical practitioners and health care agencies 80. The medical need is 
also defined as: “the quantity of medical services which - according to expert medical 
opinion and as permitted by existing medical knowledge - is to be consumed over a 
relevant period of time in order for the individual to remain or become ‘healthy’ 80.” 
 
A want is defined as a desire, also known as pleasure seeking that drives consumption 
patterns 81. It is: “the quantity of medical services which it’s members feel they ought to 
consume over a relevant period of time based on their own psychic perceptions of health 
needs 80.” 
 
Demand is defined as: “a multivariate functional relationship between the quantities of 
medical services that it’s members desire to consume over a relevant time period given the 
levels of price of goods and services, financial resources size and psychological wants of 
the population as reflected by consumer tastes and preferences for (all) goods and 
services80.”   
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Chapter Two: Entrepreneurship and Science-Based Venturing 
 
The Case of Vaccine Development 
 
Abstract 
Through applying entrepreneurial theories on science-based venturing, the innovative 
capacities of the various entrepreneurial roles contributing to the value chain are evaluated. 
Chapter 2 introduces entrepreneurial level concepts, focusing on the specific roles of 
scientists, inventors and entrepreneurs, and their contribution to the field of vaccine 
development. Entrepreneurial theories are elaborated on, and applied to Fritz Hoffman-La 
Roche and Louis Pasteur. Although the chapter focuses on vaccine development, the 
average probability of success and milestone investment per phase is contrasted with that 
of drug development. Ultimately we attempt to answer the question; which entrepreneurial 
role would be most effective in order to advance, promote, and commercialize prophylactic 
treatments against infectious diseases? 
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2.1 Introduction 
 
A major challenge in every science- and technology-driven industry is the continuous 
development of novel products, concepts, and designs based on new scientific 
achievements. It requires a bridging of the gap between the organizations that conduct 
fundamental and applied research (universities, academic hospitals, research institutes, and 
industrial research departments) and those that develop them (existing and newly created 
companies). Apart from the generation of new knowledge and its effective transfer to 
business and society (i.e., commercializing scientific discoveries), science-based venturing 
includes distinctive roles that have to be taken by scientists, entrepreneurs, and small and 
large businesses.  
 
This chapter addresses the phenomenon of science-based venturing in a biomedical field. It 
outlines the academic and business context that shapes research on viral infectious diseases 
and the development of vaccines and the strategic interaction between universities, small 
and young firms, and established companies. Fuelled by a series of scientific 
breakthroughs in the second half of the 20th century, the life-sciences sector has rapidly 
expanded and has successfully developed itself into an engine of economic growth. 
Moreover, considering technology push (new scientific breakthroughs, e.g., from stem cell 
research), market pull (aging population, quality of life) and business need (new products 
to sustain and boost turnover in the pharmaceutical and biotechnology industries), the life-
sciences sector promises to develop even further in the decades ahead of us. 
 
The societal and economic value of research, development, and the diffusion of preventive 
vaccines goes beyond measurement, and the effective application of immunization 
strategies cannot be ignored. In the words of Andre (2001): “It is undeniable that the use of 
vaccines has prevented more premature deaths, permanent disability and suffering, in all 
regions of the world, than any other medical discovery or intervention 59.” Immunization 
strategies are considered highly effective in targeting a plethora of external pathogens and 
also having the potential to prevent or even cure chronic infections, allergic conditions, 
autoimmune diseases, and cancer 82. The effectiveness of this intervention can be attributed 
to the fact that it employs the host’s own immune system to attain protection. This feature 
is inherent to the technology and distinguishes vaccines from other pharmaceutical 
products. Among the various techniques available for immunization, active vaccination is 
the most common. Given their impact on public health, vaccines form an inevitable part of 
our future. Currently, more than 900 international vaccine projects are underway 
internationally, each requiring an investment in the order of U.S. $200 to U.S. $900 
million. It has been estimated that each vaccine development project takes about 10 years 
to complete from preclinical phase to approval, and no more than 22% will attain market 
approval 83. 
 
This chapter aims to explore the different roles scientists, entrepreneurs, and managers of 
small and large firms play in advancing the health and life sciences, and apply this with a 
special focus on vaccine development. We provide a general description of the academic 
and business context to illustrate the holistic and complex nature of drug development, as 
well as the distinctive roles that scientists, entrepreneurs, and small and large firms play in 
the chain of activities from discovery to market. The chapter is divided into two main 
 19 
sections. It begins with a theoretical explanation of science-based venturing and 
knowledge transfer, including historical accounts of Louis Pasteur and Fritz Hoffmann, to 
delineate the division between the roles of inventor and entrepreneur. It then zooms in on 
the captivating world of the vaccine research and development value chain and concludes 
by defining the current state of vaccine development and the actors and issues that 
influence it. 
 
2.2 Science-based Venturing: Entrepreneurship, knowledge 
transfer and innovation 
 
The three building blocks of science-based venturing are invention, knowledge transfer, 
and entrepreneurship. In this section we will focus on the different roles that can be 
distinguished in bringing new ideas to the market: the role of researchers, the role of 
liaison officers and other transfer professionals, and the contribution of entrepreneurs and 
their small or large firms. Starting with the profiles of academic inventors, Stokes (1997) 
came up with a clear and useful 2 x 2 matrix through which he mapped the efforts of 
scientists. This included they type of research they do (i.e., basic research, more applied 
R&D, or both) and the extent to which scientists take the interests of users, sponsors, and 
other stakeholders (us) into account while carrying out their research (from no involvement 
to user-inspired basic research to pure applied research) 84. By mapping the scientists’ 
considerations of us (yes/no) and the quest for fundamental basic research understanding 
(yes/no), Stokes generated four quadrants: from basic research that is performed without 
any thought being given to practical ends (an example is the physicist Niels Bohr), to user-
oriented basic research capturing the benefits from new scientific knowledge and applying 
them effectively (a clear case of this is Louis Pasteur), to pure applied research that hops 
from one experimental project to another (Thomas Edison). The 2 x 2 matrix is completed 
by the ‘bird-watching’ quadrant in which no real question for fundamental understanding 
is present and where a (potential) consideration of use is absent, that is, watching birds just 
for the fun of it. Basic research is directed toward a more complete understanding of 
nature; it embarks upon the unknown, attempting to enlarge the realm of the possible. 
Applied research concerns itself with the elaboration and application of the ‘known’ and 
aims to convert the possible into the actual by systematically adapting research findings 
into useful materials, methods, and processes. Pasteur combined the extreme poles of the 
research spectrum by doing basic research and laboratory work in the domains of 
crystallography, biochemistry, and immunology with real-world utility potential (i.e., by 
developing preventive vaccines), but he never lost sight of the desire to advance scientific 
understanding 85. 
 
For new knowledge to be effective and for the efforts of scientists and inventors to have an 
impact, the gap between knowledge generation and its application in the market place or 
society must be bridged. For that purpose, a working relationship between inventors and 
researchers on the one hand and entrepreneurs, established firms, and consumer (patient) 
groups on the other has to established. Knowledge transfer involves the development of an 
idea from a (public or private) laboratory into a commercial product, in this case involving 
the transfer of people, knowledge, knowhow, and practices from a university or research 
establishment to industry and society. The key mechanisms in technology transfer are 
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cooperative extension and outreach to business and society on one side and patenting, 
licensing, and spin-off creation on the other 86. Whereas the former focuses on the 
development and dissemination of publicly available technologies (notably in the 
agricultural domain), the latter is aimed at making money from the inventions of public or 
corporate researchers through the sale of patents, licensing, and royalty payments, and 
equity in spin-off companies. In the former case, there is a strong belief in the free 
dissemination of knowledge, for instance, through publishing, consulting, and 
collaboration between university and industry scientists and the idea of appropriating and 
commercializing intellectual property is opposed. In the latter case, alternatively, private 
gains from academic research are sought and secrecy requirements to protect proprietary 
information are met; the university starts licensing its intellectual property rights (IPR) in 
exchange for cash, (future) sponsored research, or equity (i.e., taking shares in new 
ventures).  
 
Smith and Miner (1983) developed a typology of entrepreneurs and their businesses on the 
basis of the motivations and the management styles of the business owners and the types of 
firm they establish and run. Initially, they identified the ‘craftsman’ and the ‘opportunistic 
entrepreneur,’ as well as the organizational vehicles with which they are associated and the 
respective rigid and adaptive firm structures 87. The craftsman is characterized by limited 
education and training, low social awareness, difficulty interacting in the social 
environment, and a short-term perspective. The opportunistic entrepreneur is the polar 
opposite, having a broad education, high social involvement, the confidence in his or her 
ability to deal with the social environment, and an orientation toward the future. Smith and 
Miner (1983), together with Bracker (1992), later identified a third category, the inventor-
entrepreneur, who focuses on obtaining patents and making new products. Whereas the 
craftsman is in the business of making a better product and the opportunistic entrepreneur 
is trying to build a better company, the inventor-entrepreneur lives to invent; his or her sole 
purpose in doing business is to discover new things, obtain patents, and generate new 
products 88.  
 
Successful innovation requires a collective effort in bringing together people, ideas, and 
objects that were previously separate, and also when it comes to effective networking 
among heterogeneous ties spanning various markets and technologies. One successful 
strategy is combining what they already know and recombining existing ideas and 
practices from other industries and innovators 89. Edison, for instance, owed his success 
not so much to his ability to build something out of nothing but rather to the way he 
managed to exploit his network, borrow the ideas of others, and incorporate and recombine 
them in his breakthrough innovations. Edison is an example of a technology broker, 
someone who links otherwise disconnected communities in an attempt to maximize their 
range of connections. By doing so, a technology broker is in a better position to be the first 
to see how people, ideas, and objects from one world may provide valuable solutions in 
another.  
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2.3 Vaccine Development in the 19th Century: The scientist and the 
entrepreneur 
 
The emerging biomedical industry in the 19th century was shaped by scientists such as 
Louis Pasteur and entrepreneurs such as Fritz Hoffmann. Some of the smaller businesses 
turned themselves into large pharmaceutical companies (e.g., Hoffmann-La Roche) and 
created a value chain running from invention/discovery to actual testing and the usage of 
medical treatments. 
 
2.3.1 Louis Pasteur 
 
Whereas some scientists like Bohr, Darwin, and Einstein saw science and politics as rather 
separate spheres and never engaged much in combining their scientific and technological 
activities with education and/or selling it to the larger public, the microbiologist Pasteur 
saw science, politics, and technology as one tightly woven whole. He combined his 
dedication to science with aggressive self-promotion and a strong defence against critics, 
stating that his work had a real impact on society 85, 87. Although Pasteur was involved in 
some commercial activities during his career (he did patent but did not establish a firm), he 
showed truly entrepreneurial behaviour though his fundraising activities and the fact that 
he addressed the needs of sick people, farmers, and the beer and wine industry directly. 
Furthermore, together with others, Pasteur established a new private research institution 
that carries his name. 
 
In the early days of Pasteur’s research career, his focus was on crystallizing chemical 
structures, a technique that subsequently proved to be of major importance in alcoholic 
fermentation and drug design processes. After having read about beverage contamination, 
his research moved away from crystals and shifted toward the role of microorganisms in 
fermentation, with special reference to wine and beer, before carrying out his well-known 
studies into infectious diseases in animals and humans (e.g., anthrax and rabies). His 
research was triggered by a curiosity to solve specific scientific puzzles concerning 
microbes or germs as agents of fermentation but also as agents of disease. He was also 
driven to articulate the needs and solve the problems of farmers, textile manufacturers, 
veterinarians, beer brewers, wine growers, doctors, and their patients. 
 
At the Ecole Normale Superieure, Pasteur put together an extensive and multidisciplinary 
research team that sought to develop vaccines for chicken cholera, rabies, anthrax, and a 
score of other diseases. For this purpose, he mobilized the necessary financial resources 
and obtained funds from the national government and agricultural societies. As an 
academic researcher, Pasteur had an aggressive concern for his scholarly contributions and 
intellectual property and, to a large extent, he succeeded in keeping the method by which 
he had produced his vaccines private 90. Pasteur had also taken out several patents for his 
methods of manufacturing and preserving wine, vinegar, and beer, and for the vaccines 
against anthrax and other livestock diseases. He used the royalties from these patents to 
fund more of his research and build up a pension scheme. Although he had an interest in 
patenting his methods, treatments, and preventive vaccines, Pasteur was not motivated to 
commercialize his scientific discoveries and treatments any further, for instance, by 
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manufacturing and selling vaccines himself or through a new company in which he would 
have a substantial share 90. 
 
Pasteur was able to link his work on microbes to the interests of clients and stakeholders, 
using his microbiology laboratory and public demonstrations of the anthrax and rabies 
vaccines to fuse the interests of the stakeholders with his own drive to advance science and 
uncover the truth. For Pasteur, this would have been the ultimate source of the power a 
scientist has over society, in line with Latour’s (1983) paraphrasing of Archimedes: “Give 
me a laboratory and I will raise the world” 91. In 1888 a grand research centre in Paris was 
founded as a centre for education and research on infectious diseases. Initially, this Pasteur 
Institute relied upon private donations from all over the world and the royalties from 
Pasteur’s patents, but at a later stage, when the patent revenues declined, the institute 
became increasingly dependent on state support 90. 
 
2.3.2 Fritz Hoffmann-La Roche 
 
Unlike Pasteur, who gave us the method of pasteurization (preventing wine and beer from 
spoiling), a number of preventive vaccines, and a large and internationally well-known 
research institute in his name, Fritz Hoffmann’s fame and recognition lies in the fact that 
he established an internationally top-ranking life-sciences company and made a fortune 
during his entrepreneurial career 92. His family had made its fortune in textile 
manufacturing and trading and provided him the necessary contacts and financial support 
he needed at the beginning of his business career. Without any formal training in 
pharmacology, Hoffmann entered the pharmaceutical industry in 1893 when he joined the 
pharmaceutical merchant Droguerie. Much to the surprise of the Droguerie’s owners and 
managers, Hoffmann, together with his colleague Carl Traub, spotted an opportunity for 
in-house development of drugs and expressed their interest in buying out the company’s 
laboratory. In 1894, Hoffmann, Traub, and Company was established; Hoffmann took care 
of manufacturing and selling a small range of pharmaceutical and chemical products, his 
father supplied the majority of the start-up capital, and Traub provided the patents. 
 
A few years later, Traub and Hoffmann agreed to break up their business. With financial 
support from his family, Hoffmann effectively managed to take over and re-launched it as 
Hoffmann-La Roche and Company in 1898. Hoffmann modernized the business by 
extending small-batch manufacturing into mass-scale industrial production, pursuing a 
proactive sales policy (by simultaneously targeting the larger public, chemists, and 
doctors), and establishing a network of sales agents and distributors throughout Europe and 
the United States. In early 1900, the company started to shift its research strategy from 
extracting natural products to synthesizing compounds. Hoffman-La Roche’s products 
were already internationally available; the cough syrup Sirolin, Tubunic, and the fl u 
treatment for the 1918 epidemic sold particularly well. To obtain more money to recover 
from World War I and proactively invest in R&D, innovation, and geographical expansion, 
Hoffmann-La Roche went public in 1919. In the same year, Hoffmann retired from the 
company’s board due to ill health, and he passed away one year later. In the 1920 and 
1930s the company had started with the large-scale production of various vitamin 
preparations and by the 1950s and 1960s had begun introducing tranquilizers, such as 
Valium and Rohypnol. 
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Whereas Pasteur was more of an inventor/scientist, Hoffmann was an innovator-
entrepreneur who explored and exploited opportunities: He put new discoveries into 
practical use and brought his pharmaceutical products to the market. Hoffmann was 
particularly interested in product promotion and paid attention to the whole value chain, 
from encouraging research and looking into the patentability of a discovery to 
transforming the invention into a market innovation, producing and packaging it, and 
advertising and selling it to pharmacists. He also established an international network of 
businesses supplying the raw materials needed and the relevant sales contacts for his end 
products. Moreover, he can be considered a pioneer in large-scale manufacturing through 
standardizing packaging and preserving batch quality. 
 
2.4  Today’s Value Chain for Vaccine Development  
 
After discussing the distinctive scientific profiles and different entrepreneurial styles and 
providing two illustrative cases showing what it means to be an inventor and entrepreneur 
in the health and life sciences, this second section describes the context of vaccine 
development in current times. First, the concept of the vaccine development chain is 
described, introducing several contextual factors that potentially influence the cost and 
length of product development. Vaccines can be distinguished from other pharmaceutical 
products on the basis of the inherent feature of the intervention technology: It employs the 
host’s own immune system to attain protection. Second, the value chain of vaccine drug 
development is evaluated with the actual and potential contributions from scientists, 
entrepreneurs, and firms in mind: What are/could be their roles in advancing, promoting, 
and commercializing effective treatments for infectious diseases? 
 
To start, one has to understand the importance of the technology within the vaccine value 
chain. Epidemiology is the study of factors that influence the spread and control of 
diseases. It is a macro-level factor in light of the fact that viral infectious diseases are not 
geographically isolated and their spread is difficult to predict. The influenza epidemic is a 
perfect example of this. Influenza is a seasonal viral infection that spreads and causes local 
epidemics during the colder months of the year—autumn, winter, and spring. It has been 
estimated that during such a seasonal outbreak, 5% to 20% of the population can be 
infected, and a substantial percentage of these people develop influenza and stay at home 
for an average of 3 to 5 days 93. In most cases, the body’s own immune system is capable 
of clearing the virus; however, certain severe and sometimes lethal manifestations and 
complications can arise, particularly in high-risk groups. These groups include the very 
young, elderly, and immune-compromised individuals 94.  
 
The societal burden of seasonal influenza is measured in terms of its financial impact, 
caused by issues such as patient and caretaker absenteeism and a significantly increased 
demand on medical resources. As a result, in the Unites States alone the annual economic 
impact of influenza epidemics can reach U.S. $87 billion 93. This figure is significantly 
reduced through introducing influenza vaccines and other antiviral compounds. In case of 
an influenza pandemic, fighting the infection becomes an internationally coordinated event 
by the World Health Organization (WHO). The latest pandemic originated in Mexico 
during the first half of 2009, and the economic burden for this country alone was estimated 
at U.S. $57 million a day 94. The H1N1 virus, which causes swine influenza (called the 
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Mexican flu in some countries), was considered harmful because, in addition to the classic 
high-risk groups, individuals with no increased risk developed serious complications and 
died from the infection. In case of a pandemic threat, it is crucial that the pharmaceutical 
industry responds quickly and provides an accurate vaccine product for immunization. 
When it comes to designing a vaccine against a pandemic threat, WHO collaborating 
centres provide reference seed viruses. These are subsequently used by the pharmaceutical 
industry for production of the vaccine. Fierce competition arises as each firm wants to be 
the first in the market with the vaccine product. In the European Union, the most important 
vaccine producers during the pandemic vaccination campaign were GSK and Novartis 
producing Pandemrix and Focetria, respectively. The pharmaceutical value chain unifies 
all pharmaceutical and biotechnological product research and development, including 
vaccines, as a common factor. Once a target compound has been identified, it enters a 
linear development path that eventually results in a commercial product. Development 
consists of a series of chronological phases governed by national and international 
legislation (see Appendix). 
 
Since Edward Jenner’s cowpox immunization days, the process of developing a vaccine 
product—or any other life-science drug or medical device for that matter—has become 
significantly more complex. Since the 1950s, it has taken an average of 10 years longer to 
complete the value chain and costs more than twice as much as it had previously 95, 96. As a 
matter of fact, increasing development times demand even more resources, including 
financial investment. Estimations of the cost involved for one pharmaceutical product 
completing the value chain easily surpasses U.S. $1billion 97. This statistic also 
compensates for the investment in discontinued projects, yet such calculations do not 
usually distinguish between new chemical entities and vaccine products. Several 
explanations for the extended value chain are listed below 98: 
 
x International harmonization efforts, the process intended to streamline the 
value chain at a country-to-country level. 
x The generation of rules that aim to prevent medical incidents. 
x The generation of rules that aim to prevent fraud. 
x A rise in public consciousness regarding the realization that vaccine 
products administered to humans require both ethical regulation as well as 
adequate business standards. 
x Technological resources and theoretical knowledge on the immune system 
increases experimental complexity. 
 
On the one hand, there are necessary and legitimate reasons for an increase in both the 
duration and cost of the value chain. On the other, the value chain has to be flexible 
enough to allow for quick product development and distribution during the event of an 
epidemic or pandemic. Developing a vaccine product targeting a viral infectious disease is 
an unmet medical need within an international political setting. With current modes of 
transportation, a disease can spread to other continents in a few hours (for example, recent 
outbreaks of SARS and H1N1). Governments, medical facilities, and industries all over the 
world are affected and have to respond with appropriate strategies. At the project-level, 
there are two elements that play an important role: the cost of investment and the statistical 
chance of a product completing the value chain (Figure 2.1). Developing a vaccine is a 
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lengthy and costly endeavour involving a risk of termination due to unforeseen 
circumstances 99. Terminating a project is not an easy decision and represents a burden at 
the individual and societal level for several reasons. First, the patient population does not 
receive appropriate treatment. In the case of an infectious disease, human-to-human spread 
of the pathogen can occur at an uncontrollable rate, posing a public health risk. Second, 
resources invested in the project are lost. So where does the money come from? A project 
is financed from several sources including governmental subsidies and venture capitalists, 
for example. In view of the fact that government subsidies are generated from national 
taxes, discontinuing a project also affects society at an economic level. 
 
Figure 2.1 Relationship between project success rate (Right) and cumulative milestone 
investments (Left). 
 
 
    
 
If we regard the value chain as being segmented into various phases, the option of 
milestone payments for every step are useful as this spreads the risk (see figure 1, right). 
Nearer the ending of a phase, safety and efficacy data is collected in order to decide 
whether to continue on to the subsequent development stage. One may believe that after 
the completion of a phase, when more supportive medical evidence is available, the 
decision to proceed will become easier. Conversely, there is actually more at stake; it is 
evident that when dealing with an investment of this magnitude, this inherently raises the 
pressure to succeed the further along the value chain it is. Risk is usually calculated as a 
product transition percentage (at market level), indicating the amount of products that 
make the transition from one phase to the next, with the ultimate goal of reaching the 
market (see figure 1, left). These types of calculation are usually retrospective analyzes 
based on historical accounts and are descriptive.  
 
It is believed that the value chain starts with 5,000 to 330,000 candidate molecules during 
the R&D stage, from which only one molecule attains market approval. By combining 
both the financial investment and transition rates of a product, we attain micro-level 
context information in the form of a risk profile (Figure 2.2). This information is highly 
valuable when making decisions on whether to invest in later phases and whether to 
continue with the project. As seen in figure 17.2, the further along the value chain, the risk 
correlates negatively with the investment. However, there is no such thing as 100% 
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certainty at any moment, and a project can be terminated for any number of reasons 99. 
From the financial perspective, it is crucial to discontinue a project as early as possible. 
Risk is always relative to something; hence, the figure depicts the risk profile for 
pharmaceutical products as well. In short, vaccines require a lower investment when 
compared to biopharmaceuticals. Moreover, it has been estimated that for every vaccine 
candidate that initiates the value chain at preclinical phase, 22% enter the market as 
commercial products. This percentage is higher for biopharmaceutical products 100. 
 
Figure 2.2  Relationship between project cost and success rate.  
Each point on the curve corresponds to a particular value chain phase - labelling applies to both 
curves. Below the graph, there is an indication on the window of opportunity, where the entrepreneur 
can benefit most (Combining 82, 101-103). 
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2.5  Today’s Entrepreneurs in Vaccines and Other Life Sciences  
 
In a perfect world, each initial product entering the value chain would also complete it 
successfully. Fortunately for small biotech companies, this is not the case and there is 
room for entrepreneurs to enter the industry and find a position in the value chain. 
Entrepreneurial activity in vaccine R&D is closely linked to the concept of productivity 
and innovation. A standard measure for the productivity of the pharmaceutical industry is 
the annual license approvals by the regulatory bodies, such as the United States Food and 
Drug Authority (FDA) or the European Medicines Agency (EMA). The approval of these 
licenses is critical for market entry and is the ultimate goal when starting a project. Since 
the 1970s, the biopharmaceutical industry has been haunted by a so-called ‘productivity 
gap,’ an increasing amount of resources directed at R&D departments with a seemingly 
limited number of products entering the market 76. Contrary to popular belief, when 
looking at the graph published in literature 104, a positive trend historically has been 
reported in terms of the productivity of the industry. The data is collected for U.S. 
pharmaceutical product performance only; however, it is assumed that a similar trend can 
be observed for any therapeutic category within the global pharmaceutical industry, 
including vaccines. Nevertheless, it remains a fact that the proportion invested in the value 
chain compared to the quantity of product approvals is unbalanced. Entrepreneurs can 
contribute in multiple ways to vaccine development as the various phases of the value 
chain require different entrepreneurial strategies and skills. 
 
As previously mentioned, Smith and Miner (1983) and Miner, Smith, and Bracker (1992) 
argue that there are several types of entrepreneur, each with specific managerial 
motivations and who will establish different firms. Within each stage of the 
pharmaceutical value chain, all three types remain active throughout the value chain; 
however, there are certain preferences as to which development stage is most attractive 
(Appendix 2.7). The overall aim for entrepreneurs in the life sciences is to develop 
technology, knowledge, or services that increase the efficiency of (certain parts of) the 
value chain and ultimately strive for market approval. The ‘craftsman’ is involved with 
making a better product and is predominantly active during the R&D and preclinical 
phases, although he or she can contribute during all clinical phases as well. In this case, the 
craftsman does not have a low level of education or training as the industry is run 
according to standard operating procedures. An example of a craftsman is the scientist who 
develops compounds; he/she has excellent knowledge of the product but does not take the 
target patient population into consideration (e.g., developing a lotion that treats the 
indication but leaves a yellow stain on the skin). 
 
The opportunistic entrepreneur concerned with building the business is most active within 
the emergence phase of the industry. Although the risk is high, it is within this time frame 
that the financial benefit accelerates most steeply, and there is ample opportunity to 
increase efficiency of the value chain and prevent project termination while doing so. From 
clinical phase III onward, the value chain is less attractive to entrepreneurs; this phase 
usually has a set outcome and requires approximately 33% of the total value chain 
budget102. Only under rare circumstances is a project discontinued during a clinical phase 
III trial. Moreover, a small-to-medium-sized firm does not have the financial resources or 
physical capacity necessary to complete a phase II or phase III trial and aims to be 
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acquired, via a merger or acquisition deal, by the pharmaceutical industry as an exit 
strategy. From this point onward, entrepreneurship continues in the form of ‘intra-
preneurship’ within the larger pharmaceutical company.  
 
The inventor-entrepreneur, known to ‘live for inventing,’ also benefits from the window of 
opportunity during the industry’s early stages. He or she is not only able to recognize an 
opportunity but will also create more efficiency in the process. An example of a current 
initiative from an inventor-entrepreneur is the Artemis Wildlife Health InstituteA. If 
considering epidemiology, it has been estimated that approximately 70% of pathogens 
descend directly from wildlife or domestic animals 105. With this information, 
entrepreneurs can unify veterinarian and wildlife centres with existing human R&D 
research units, for example. By developing this type of multidisciplinary interaction, 
infectious pathogens can be studied and strategies can be designed to identify pathogen 
transmission more efficiently and rapidly. More specifically, animal-to-human and 
subsequent human-to-human transmission can be identified using knowledge about the 
pathogen’s underlying genetic changes as well as the predisposing factors that cause or 
facilitate these events. In this way, emerging epidemic or pandemic threats to public and 
animal health can be identified more effectively, allowing for intervention strategies to be 
implemented in a more timely manner. 
 
2.6 Conclusion 
 
The objective of this chapter was to explore the distinctive contributions made by the 
academic inventor and the innovative entrepreneur toward the development of vaccine 
drugs. The complex phenomenon of science-based venturing describes the relationship 
between scientific knowledge creation, and its effective commercial and societal 
exploitation by public and private sector. The historical accounts of Pasteur and Hoffmann 
indicate two different approaches to science-based venturing: The former was invention 
driven, whereas the latter was more commercially driven. In the pharmaceutical and 
biotechnological industry, vaccines are considered a fundamental innovation. Historically, 
on a global scale, vaccination has contributed greatly to decreasing human mortality rates 
as a result of infectious diseases and maintaining public health, for example, through the 
eradication of polio. With an annual compound growth rate of 23% since 2004 106, this 
therapeutic intervention will remain an essential part of preserving our health in the future. 
 
The main themes of this chapter address the organization of the value chain during drug 
development and the roles scientists and entrepreneurs play in it. First of all, as a result of 
certain medical incidents in the past, the necessary rules and legislation governing the 
vaccine value chain have shaped it into its current lengthy, costly, and rigid format. 
Nevertheless, in the case of a pandemic threat, governments, industry, and regulators have 
to react quickly, requiring the value chain to respond with a certain degree of flexibility. 
This represents a delicate balance, taking into account the fact that vaccines are 
administered to healthy individuals and high-risk groups and there is a zero-tolerance 
attitude toward side-effects. Another theme involves the entrepreneur and the risk profile 
                                                          
A Visit: http://www.artemiswildlifehealth.eu/  
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for vaccine development. Entrepreneurs endeavour to increase the efficiency, innovation, 
and success of vaccine development during the initial phases of the value chain. Here, 
entry cost is relatively low and the return on investment is potentially higher, even though 
there is a high failure rate. Project discontinuation not only represents a social loss 
(without immunization the spread of infectious diseases cannot be easily controlled) but 
also societal loss expressed in financial terms. Entrepreneurs are more commonly active 
during the early stages of the vaccine value chains as this phase offers the main window of 
opportunity to enter the industry. The fact remains, however, that the investment and 
productivity trends are not in proportion to one another. Additionally, the value chain is a 
holistic procedure that requires input from various disciplines and actors. The ultimate goal 
in life-science venturing is the development of knowledge, technology, and products while 
abiding by international ethical, safety, and efficacy standards.  
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Chapter Three: The Gold Industry Standard 
 
Risk and Cost of Drug Development Revisited 
 
Abstract 
Gold dimensions of pharmaceutical drug development indicate that it takes on average 
11.9 years, with an investment around US$ 0.8 Billion, to launch one product on the 
market. Furthermore, approximately 22% of the drug candidates successfully complete 
clinical testing. These universally acknowledged proportions largely originate from one 
single, much cited publication; Dimasi et al (2003). However an additional six articles 
describing new chemical entities (NCE) development were identified, which contain little, 
if any, information on vaccines. Published cumulative success rates range from 7% to 78% 
and investments calculations span US$ 0.8 to 1.7 Billion. Obviously this disserves further 
clarification? 
 
Pronker, ES 
Weenen, TC 
Commandeur, HR 
Claassen, E 
Osterhaus, ADME 
 
Vaccine (2011) 29; 35: 5846 - 5849  
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3.1 Introduction 
 
There appears to be a state of contradiction within the pharmaceutical industry; while more 
resources are being directed towards research and development (R&D), the number of 
market approved products does not seem to keep an equal pace 107. This phenomenon, also 
referred to as the productivity gap 108, only considers the market entry level of the product 
development value chain. The value chain describes the chronological phases a drug 
completes to determine its safety and efficacy profiles, and consists of; target 
identification, lead selection, pre-clinical phase, clinical phase (I, II and III), registration, 
market approval and post-marketing clinical phase IV. Development up to clinical phase 
III is covered in this article. 
 
Possible explanations for this gap include targeting more complex diseases and dealing 
with stringent regulatory processes 27. Nevertheless; technological innovations in the first 
two phases – resulting in efficient high through-put screening of candidate compounds – 
does not limit the input end of the value chain, leading us to conclude that obstacles to the 
pharmaceutical industry’s productivity must lie elsewhere. 
 
During both pre-clinical and clinical stages, the industry’s productivity can be evaluated 
using the basic parameters of length, risk and cost of the individual value chain phases. 
Given that development timelines have stayed reasonably constant since the 1990s 109, risk 
and cost aspects of vaccine and drug development are subjects of debate. For example, 
information on the risk of drug development is crucial when deciding on project 
continuation or discontinuation, and is usually expressed as a phase transition ratio. The 
cost associated with pursuing the launch of one product is bound to increase over time, at 
least in part due to the sobering reality that each success story has to cover the expenses 
associated with the discontinued programmes 107. The pharmaceutical industry faces the 
continuing challenge of rendering the value chain as efficient and productive as possible, 
through reducing overall attrition rates and costs, while remaining innovative and 
competitive in multiple disease areas. 
 
Commercial vaccine and drug development can be described using the following gold 
parameters addressing the length, risk and cost of the value chain; one successful product 
has an average development timeline of 10 to 16 years, with a 22% chance of completing 
the clinical phases (Clinical trials phase I, II and III), and requires an investment that easily 
surpasses the US$ 0.8 Billion 110, 111. As these figures are largely based on little more than 
a single publication by Dimasi et al. 110, we conducted a literature review that resulted in 
an additional six relevant papers. In view of the largely conflicting data presented in the 
respective publications, we critically evaluated the methodologies used and the estimates 
of the risks and costs associated with vaccine and drug development. 
 
3.2  Methodology 
 
The literature scan was conducted using a combination of Metapress, Pubmed, Google 
Scholar and Scirus public search engines, applying relevant search terms on the theme, 
including risk profile, new chemical entity (NCE), pharmaceutical value chain (PVC), drug 
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development, attrition-, transition-, success-rate, and combinations thereofA. Relevant peer 
reviewed articles published since 1995 were selected based on content. Publications 
referencing the risk and cost statistics directly from Dimasi et al. 110, 111 were excluded. 
 
3.3 Results 
 
3.3.1 Drug development success rate 
 
All seven articles report figures on drug development success rates, yet the results are 
distributed between 7% 112 and 78% 113 (Figure 3.1). Such dramatic range in observations 
suggests that calculating the productivity for the entire pharmaceutical industry is 
challenging and perhaps sensitive to multiple variables. Some articles are more detailed 
than others when it comes to describing the methodology and considerations for estimating 
the cumulative risk of drug development (Table 3.1). 
 
Figure 3.1 Drug development cumulative success rates  
Measured from the start to the end of the measurement. Sorted by probability of success, as reported 
in literature 27, 110-115 Results are not indicative for an approval trend over time. 
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A possible explanation for the observed range can be attributed to the sources from which 
the data sets were compiled. Some authors used a single source to develop the data set, 
referred to industry-sponsored resources or to private communications. Furthermore, it is 
unclear in most publications which types of NCEs are evaluated and to what extent 
vaccines are taken into account. 
 
Second, most publications do not justify the sample selection procedure. Various time-
frames have been selected for review, ranging from a three-year window 112, 114 to a 
thirteen-year period 113. The quantity of compounds selected for analysis varies from 13 114 
to 1910 113. Moreover, some articles include preclinical phase in the calculation, whereas 
others exclusively analyze the clinical phases. 
As a final point, the methodology of analysis in most publications is unknown. In addition, 
some research groups did not clarify whether the effect of a third variable was taken into 
consideration. Data stratification by clinical phase and therapeutic class 27, 111, 113 product 
origin 111, 112, firm experience 113, 116 or product type 115, reveal significant variations in 
compound success rates. 
 
3.3.2 Drug development cost 
 
The cost for developing a NCE along the pre-clinical and clinical phases is usually 
classified information, not readily disclosed by pharmaceutical companies. Hence the 
estimates in the selected publications are based on assumptions, making the results 
sensitive to reporting bias 117. 
 
In three of the previously identified articles, estimates on the cost of developing a NCE are 
reported – US$ 0.8 110, 0.9 27 and 1.6 Billion 114. The research groups defined the risk of 
development and the cost involved independently from each other. Success rates are also 
graphed, providing an indication of the risks involved with the investment (Figure 3.2). 
 
The Dimasi paper 110 has the most descriptive methodology. The data published in this 
article has been cited by many sources, including recent PhRMA reports 102. It has largely 
been adopted by the pharmaceutical industry as a gold standard, even though the 
credibility of the results have been challenged 117, 118. The calculation is based on 68 NCE 
using an interview tool, combining out-of-pocket and real cost for products in pre-clinical 
phase through to entering clinical phase III. The other two research groups quote figures 
from commercial reports for which methodologies remain confidential. 
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Figure 3.2 Cumulative investment for a NCE completing the clinical phases (Bar graph), 
including the cumulative risk (plotted point) 27, 110, 114.  
All cost calculations exclude vaccines. The graph does not show the trend; the lower the investment, 
the higher the success rate. Instead, these are three independent cost and risk calculations. 
 
 
 
 
3.4  Discussion 
 
As indicated in the leading articles, there is no standardized format for NCE risk and cost 
calculations. Cumulative success rates indicate substantial differences ranging from 7% to 
78%. If against all odds the compound reaches the market, it will have required an 
investment of US$ 0.8 Billion or more. We propose a few justifications for the range in 
published parameters. 
 
First, NCE products cannot be generalized. Most publications use aggregate data 
neglecting potential third variable influences on the success rate. This has been 
demonstrated in articles differentiating between therapeutic class or the origin of the 
molecule, revealing significant diversified success rates across categories.  
 
Second, data is collected from a range of sources. Sometimes including combinations of; 
commercially available marketing reports, scientific publications, industry sponsored 
databases, and confidential resources. Research gains credibility when multiple sources are 
consulted, yet considering the limited justification for the choice of sources and the fact 
that data from the latter two options makes replication challenging, external validity is 
questionable. 
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In most publications, the chosen parameters building the dataset are left unexplained. For 
example opting for a 2-year observation window when development takes on average 10 
years or more. Some articles do not explain how data on failed or terminated projects have 
been considered for the success rate and cost calculations. Moreover it is unspecified 
which processes are included in the pre-clinical phase. It proved unclear in most cases 
whether the parameters are due to practical limitations – such as data availability – or to 
predetermined variables. Without such transparency, ambiguous data set descriptives or 
calculating protocols challenge the scientific quality of the statistics, and it remains 
debatable whether the product transition rates published are representative for the global 
pharma industry. 
 
Finally one may question whether it is even possible to accurately determine the cost for 
the development of a drug or vaccine. It is imaginable that larger firms have “fluid” 
resources and can easily allocate them to a priority programmes when compared to a 
company with only a limited number of products in the portfolio. The current industry 
descriptor, by Dimasi et al. 110, analyzes risk and cost for the top pharmaceutical 
companies. Without randomization of the product type or sponsor company (size), the 
results are prone to selection bias. 
 
It can be concluded that in general, developing drugs involves high attrition rates and 
requires large investments. In addition it is challenging to accurately determine the 
transition rates and cost for a product in pre-clinical and in clinical development, to 
represent the behaviour of development for the entire pharmaceutical industry. All articles 
cited in this review paper present an analysis of their unique dataset, and the results should 
not be compared to one another but interpreted as indications at best. Considering that 
determining the risk and cost for NCE and vaccines requires a more holistic approach, we 
would argue that there is no gold standard.   
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Chapter Four: Risk in Vaccine Research and Development Quantified 
 
Abstract 
To date, vaccination is the most cost-effective strategy to combat infectious diseases. 
Recently, a productivity gap affects the pharmaceutical industry. The productivity gap 
describes the situation whereby the invested resources within an industry do not match the 
expected product turn-over. While risk profiles (combining research and development 
timelines and transition rates) have been published for new chemical entities (NCE), little 
is documented on vaccine development.  
 
The objective is to calculate risk profiles for vaccines targeting human infectious diseases. 
A database was actively compiled to include all vaccine projects in development from 
1998 to 2009 in the pre-clinical development phase, clinical trials phase I, II and III up to 
Market Registration.  
 
The average vaccine, taken from the preclinical phase, requires a development timeline of 
10.71 years and has a market entry probability of 6%. Stratification by disease area reveals 
pandemic influenza vaccine targets as lucrative. Furthermore, vaccines targeting acute 
infectious diseases and prophylactic vaccines have shown to have a lower risk profile 
when compared to vaccines targeting chronic infections and therapeutic applications.  
 
In conclusion; these statistics apply to vaccines targeting human infectious diseases. 
Vaccines targeting cancer, allergy and autoimmune diseases require further analysis. 
Additionally, this paper does not address orphan vaccines targeting unmet medical needs, 
whether projects are in-licensed or self-originated and firm size and experience. Therefore, 
it remains to be investigated how these - and other - variables influence the vaccine risk 
profile. Although we find huge differences between the risk profiles for vaccine and NCE; 
vaccines outperform NCE when it comes to development timelines. 
 
Pronker, ES 
Weenen, TC 
Commandeur, HR 
Claassen, E 
Osterhaus, ADME 
 
Plos One (2013) [Accepted]  
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4.1 Introduction 
 
Human life expectancy has increased due to the implementation of hygiene, sanitation and 
vaccination. Immunization strategies - of which the use of vaccines is the most important - 
have prevented more premature deaths, permanent disability, and suffering, in all regions 
in the world, than any other medical intervention 5, 119-121. Vaccines are the most cost-
effective strategy with the potential to prevent - or even cure - acute and chronic infections, 
allergic conditions, auto-immune diseases and cancer 82, 122. Prophylactic and therapeutic 
vaccination leading to both individual and herd immunity as well as symptom relief during 
disease progression respectively, will continue to be of fundamental value in maintaining 
public health in the future 123, 124. 
 
Unfortunately, as with the pharmaceutical industry, also the biotech sector is affected by 
the so-called productivity gapA 76, 77. Developing a human vaccine from the preclinical 
phase to registrationB requires an increasing average investment of approximately US$ 200 
to 900 million 82. However, merely 22% of the initiatives were forecasted in 1996 to 
successfully reach the market after 10 years of development 125, 126. This imbalance is to a 
large extent caused by rising cost of research and development (R&D), biological and 
technical challenges associated with targeting more complex diseases, competition with 
better standards of care, larger scale of clinical studies to prove safety and efficacy and last 
but not least an increasingly stringent regulatory environment 97, 99. From the perspective of 
the patient, and in financial terms: the subsequent attrition rate is substantial and should be 
improved. 
 
Value chain descriptives - including, but not limited to; phase duration and transition rates- 
are important parameters for investors seeking strategic financial advice. The result of 
combining these two dimensions is a relatively accurate physical indication of the 
productivity at different development stages. The current benchmark on methodologies for 
determining risk profilesC is published by Dimasi et al (2003) 97, and applies to new 
chemical entities (NCE). To date, there is limited documentation on vaccine development. 
Two articles in particular - one from 1996 127 and a more recent publication from 2011 128 - 
focus on value chain descriptives comparing NCE and vaccine profiles. We intend to take 
the analysis one step further and introduce the additional variable of the target infectious 
agent. 
 
  
                                                          
A The productivity gap describes a situation within an industry whereby the invested resources do not match the 
expected product turn-over  
B Also known as the value chain; the consecutive development stages a vaccine or medical compound progresses 
through to accumulate value and become established as a safe, effective and qualitative product 
C Risk profile; combining data on average phase duration with rates of projects transitioning between value chain 
phases 
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4.2 Objectives 
 
The present paper offers an empirical analysis on the value chain risk profiles for human 
vaccines in development from 1998 to 2009. We hypothesize that current vaccine risk 
profiles behave in a pattern similar to those described for NCEs: since 1983 to 1994 129 the 
overall phase duration is postulated to have lengthened but the market entry probability is 
expected to remain relatively constant 130. Moreover, by stratifying data according to 
infectious disease areas, we aim to identify the development stages during which attrition 
rates are highest. In the competitive landscape where resources are limited, the overview 
allows for vaccine developers and investors to anticipate common project-level challenges 
for the particular disease area.  
 
4.3 Methodology 
 
Our methodology and assumptions are based on Struck 131, and Dimasi 132. Data is 
collected on five value chain phases on the basis of availability, observing human vaccines 
in development from 1998 to 2009A. An active research strategy is chosen to develop the 
proprietary dataset, cross-referencing various sources including; commercial database 
(MedtrackB), governmental sources, company sources open to the public, official press 
statements and scientific publications. 
 
Using the commercial database as a starting point, a total of 902 vaccine candidates during 
any stage of development were included in the datasetC. It was assumed that the database is 
current and contains an accurate record of all vaccine projects, making randomization 
unnecessary. Consequently the data was filtered according to specific in- and exclusion 
criteria (Table 4.1). By defining the dataset we assumed that phases do not overlap, and 
that each vaccine progresses through the same stages in chronological order. 
 
Phase duration was determined by the average number of years a vaccine candidate takes 
to complete a development phase. Discontinued projects were not included in this 
calculation since the decision can occur at any moment distorting results; 456 vaccine 
projects remain eligible. For practical reasons we consider a year to have 360 days. 
 
The second element of the risk profile constitutes the transition probability, which was 
determined by applying the formula as described in 133. Furthermore, the cumulative 
transition ratio is taken to represent the market entry probability. It indicates the proportion 
of vaccine candidates that developed successfully from PC to the highest attainable 
development phase. All vaccine projects in the dataset were included in these calculations.  
 
                                                          
A The five development phases included in the analysis; Preclinical (PC), Human Clinical Trials Phase I-III (PI-
III) and Regulatory submission (RS). Discontinued projects (D) are also included. Where available, data is 
updated to 2010. 
B  Medtrack © is opted due to accessibility, and is compatible with Pharmaprojects ©. 
C  Data was collected on the 12th of May 2010 showing 1495 entries. By excluding products on the market, in 
post-marketing trials, or where no details were found (NA), 902 unique products remain. 
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Lastly, data was stratified according to therapeutic area for investigating this third variable 
influence on the phase duration and transition probabilities. Furthermore, within this 
infectious disease category, data on vaccines against acute infections, chronic infections, 
preventative indications and therapeutic indications are analyzed separately. Nevertheless, 
in order to recognize the significance of the disease area, risk profiles are placed into 
context of the disease burden and invested resources. The estimated patient population is 
taken to represent the former aspect; whereas the latter was measured by total sum of the 
value of merger and acquisition (M&A) dealsA. The disease areas covered by the majority 
of vaccine projects are presented in this paper.  
 
Table 4.1 In- and exclusion criteria for fine-tuning the dataset, inspired by 110, 111, 115 
 
Inclusion criteria Exclusion criteria 
EMPHRA Code J7 = human vaccine 
product, prophylactic and therapeutic. 
Vaccine product undergoing post-
market clinical trials for additional 
indications  
Vaccines target human infectious diseases 
caused by; viral, bacteria, fungi, parasites, 
bacterial toxins and unspecified infectious 
agents.  
Vaccines targeting cancer, allergy and 
auto-immune indications. 
The database entry has descriptive 
information on the product; sponsor 
company, therapeutic area, at least one 
date indicating the state of the current 
development phase 
The vaccine product cannot be found on 
at least one other source.  
Except for products in PC or D phases, 
as these are underreported 
Product is in the following phases 
according to the database; PCB, PIC, PIID, 
PIIIE, RSF, DG.  
Products in the following phases 
according to the database: MH, PMI, 
NAJ, FK. 
Start of PC phase in 1998 Duplicate entries 
 
  
                                                          
A The commercial database Pharma ETrack © is consulted on financial statistics of M&A. The sum of M&A 
activity in US $ Million since 2004 is calculated as an indication for the amount of resources the biotech 
industry invests in the particular disease area.  
B  Preclinical Phase 
C  Human clinical trials Phase One 
D  Human clinical trials Phase Two 
E  Human clinical trials Phase Three 
F  Regulatory submission to allow market entry 
G Projects discontinued for any reason during any stage of the following stages of vaccine development; PC, PI, 
PII and PIII 
H  Market phase 
I  Post-marketing, also known as human clinical trials phase four 
J  No information available 
K  Failed or terminated vaccine products. In other words, products that have received regulatory market approval, 
but have been withdrawn from the market for any reason.  
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4.4 Results 
 
The filtered dataset contains 605 unique human vaccine candidates during any stage of 
development, from 188 individual firms covering over 60 therapeutic areas. The risk 
profile for the average vaccine in development from 1998 to 2009 only partially behaved 
as predicted (Figure 4.1, black curve); the timeline has lengthened by 0,71 years, yet the 
cumulative success rate is lower at an estimated transition probability of 0,07 (Table 4.2). 
On account of the sizeable standard deviations, we would advocate that risk profile 
parameters delineating the entirety of the dataset should only be interpreted as an 
indication for the general development trend of the vaccine manufacturing industry. 
 
When dividing the data according to the third variable - areas of therapeutic intervention - 
49% of the vaccine pipeline covers 5 conditions. Furthermore, Japanese Encephalitis (JE) 
vaccine projects are highlighted due to multiple recent product approvals. These include; 
Ixiaro © (Intercell AG, also known as Jeev © and Jespect ©, available since 2009 in 
various countries), and beyond the scope of the dataset Encevac © (Kaketsuken, in Japan 
since Jan 2011) and Imojev © (Sanofi, available in Australia and Thailand since July 
2011). The remaining disease areas are not represented by a sufficient quantity of vaccine 
projects to attain statistically significant comparisons.  
 
By far the most lucrative business opportunity is created by pandemic influenza. In this 
saturated environment, efficiency is the key word if vaccine manufacturers desire to 
maintain a competitive advantage. As the current manufacturing capacity for influenza 
vaccines is limited at 900 million dosages 134, innovations are namely pursued in areas 
including adjuvant development, delivery system and manufacturing technology 135. 
Nevertheless, pandemic influenza vaccine preparedness is a unique and rare situation that 
should not be compared to vaccines targeting other disease areas.  
 
Pandemic influenza preparedness efforts are largely aligned with World Health 
Organization’s advice to national governments on societal, antiviral and vaccine strategies, 
based on monitoring the threat-level of emerging potential pandemic influenza viruses 136. 
Since purchasing vaccines for immunization campaigns is coordinated by national 
governments, they are responsible for ensuring sufficient access from the early stages of an 
influenza pandemic onward. Over the past few decades, several governmental bodies 
followed the WHO preparedness advice and proactively sought advanced purchase 
agreements with vaccine manufacturers. Such agreements led vaccine manufacturers to 
anticipate an increasing demand for influenza vaccines, and as a result they invested in 
expanding their manufacturing capacity.  Furthermore, during the 2009 H5N1 influenza 
pandemic, vaccine acquisition by individual governments proved to be an inefficient 
system, and the European Committee (EC) responded by establishing a joint procurement 
initiative for future pandemic threats in November 2011  137, 138. Obviously the 
sustainability of such provisions is largely dependent on the political will and compliance 
of individual member states and it probably will be hard to implement in the current era of 
‘post-pandemic fatigue.’ 
 
 
 43 
Figure 4.1 Risk profiles for the selected disease areas,  
Risk profiles Combine phase duration with the cumulative transition probabilities as indicated by 
market entry probabilities. Rank order indicates quantity of projects in data set. Data points are 
labelled on the All Data curve; this labelling also applies to the other curves. 
 
 
 
Additionally, JE represents an attractive target for vaccine developers; with merely 11 
firms in our dataset investing in R&D, over 1 in 10 initiatives successfully attain 
regulatory submission phase. The short and steep risk profile presumes half the candidates 
from PC progress to subsequent PI trials. Nevertheless, due to the low number of candidate 
vaccines in later stages of development, we believe the timeline is underestimated.  
 
The foremost challenge in vaccine development is reducing the average transition rate 
from clinical phase II to III. Between these value chain phases the risk profile 
incorporating all data has an estimated transition probability of 0.21. It represents the 
highest attrition rate when compared to the productivity of the other phases. Both Anthrax 
and Malaria risk profiles confirm the bottleneck, as project development activities do not 
advance beyond PIII. The phenomenon has been recognized in NCE development, and we 
believe the underlying mechanisms and explanations are also applicable for vaccines139-141. 
 
A second major obstacle is a successful transition from clinical phase III to regulatory 
submission. Such bottlenecks are evident in Pandemic Influenza, and Hepatitis B vaccine 
(HBV) risk profiles, whereby the attrition rate for HBV candidates is calculated at an 
astonishing 50%. HIV/AIDS projects are also affected by significant attrition rates 
between these stages. Reasons for submission failures have been described for NCEs, and 
we assume similar arguments are relevant 142.  
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Data was further granulated into vaccines targeting acute versus chronic indications and 
prophylactic versus therapeutic applications (Figure 4.2). According to the dataset, 
vaccines targeting acute infectious diseases, as well as prophylactic vaccines clearly have a 
lower risk profile when compared to vaccines targeting chronic diseases or therapeutic 
applications.  
 
Figure 4.2 Vaccine risk profile granulating acute versus chronic infections and 
prophylactic versus therapeutic vaccines.  
Groups are stratified from 100% of the data from the dataset. Percentage per group included.  
 
 
 
As a final observation: it is generally assumed that a higher disease burden - preferably in 
the industrialized world 143 - is an incentive to dedicate resources to that particular disease 
area (Figure 4.3; Table 4.2). As an example of the opposite being the case sometimes: 4% 
of vaccine development projects target anthrax, while the infection is highly uncommon 
and related to biological-warfare 144. 
 
4.5 Conclusion 
 
Risk profiles are important descriptive tools providing indications on possible future 
vaccine project outcomes, essential for strategic decision making. In general, the more 
recent vaccine development projects from 1998 to 2009 showed a longer timeline with a 
lower probability of market entry than those from 1983 to 1994 145. What could partially 
explain the increased phase length could be the fact that the ICH-E6 Good Clinical 
Practice guidelines came into effect after Struck’s publication in 1996, which has 
influenced clinical research on a global scale. However, we feel that the phase lengths 
calculated are not fully representative for the actual situation. Certain preliminary R&D 
activities - such as in silico lead selection and toxicity screening - taking place prior to 
patenting are not represented in the dataset. We believe that when these procedures are 
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taken into consideration, the actual development timeline is expected to be even longer 
still.  
 
Additionally, the lengthening timelines for vaccine development may be influenced by the 
fact that the so-called ‘low-hanging fruits’ has already been picked. Data confirms that the 
majority of vaccine R&D projects encompassing incremental innovations targeting disease 
areas with known correlates of protection have a shorter development timeline when 
compared to more radical vaccine innovations 146. Nevertheless, vaccine timelines remain 
significantly shorter when compared to NCE development. 
 
Figure 4.3 Combining the cumulative success rate with the contextual factors of disease 
burden and size of investment (indicated by the size of the bubble) 
 
 
 
 
Clarifications for the discrepant transition probabilities between our dataset and previous 
articles expediently relate to data collection methodologies. Moreover, stratifying data 
according to acute or chronic indications as well as therapeutic or prophylactic application 
revealed significant variations in transition success. This confirms that one risk profile 
cannot represent the productivity of the overall vaccine development field, and the effect 
of a third confounding variable is essential information. 
 
Essentially, infectious diseases are different from cancer, and both are fundamentally 
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allergy/autoimmunity should be analyzed separately. Moreover, this paper does not 
address orphan vaccines targeting unmet medical needs, whether projects are in-licensed or 
self-originated and firm size and experience 99, 147, 148. Therefore it remains to be 
investigated how these other variables influence the vaccine risk profile. 
 
Vaccine development is a risk intensive exercise and requires substantial investments. As 
indicated by the risk profiles: the ratio of success to failure is in favour of the latter. Both 
the burden of disease and the magnitude of invested resources into a project targeting a 
specific infectious agent do not correlate with a higher success rate. Substantially resources 
are dedicated to HIV/AIDS, even though within the scope of our dataset there are no 
regulatory approved vaccines. It is interesting to note that preventive vaccine development 
against JEV - a virus that causes acute infection - may not be considered such a lucrative 
target as the market size is too limited to guarantee a rapid return on investment. Obviously 
other criteria are used for vaccine target selection 149, 150.These high rates of attrition need 
to be reduced in order to sustain business case growth 151, and respond appropriately to 
public health demands. 
 
Several considerations apply to this study. First, we have assumed that the database on 
commercial vaccine development - on which the dataset is based - keeps an accurate 
record of all vaccine development projects currently in any phase of development. The 
dataset we compiled is unique; however the explicit delineation of methodologies should 
allow other research groups to replicate procedures. Additionally, phase lengths are 
influenced by the spread of the data points. The majority of the vaccine development dates 
(>50%) were collected after the year 2000 implying the spread of points is not equally 
distributed within the dataset. This either suggests that the earlier years of the selected 
timeframe are underrepresented, or that the actual quantity of projects has increased over 
the years.  
 
This paper provides a descriptive historical account of vaccine development between 1998 
and 2009, and does not have the ambition to forecast any trends. Moreover we have not 
addressed the numerous reasons that may lead to project termination, and do not disregard 
the necessary legislative requirements in the development of ethical, safe, effective, and 
high quality vaccines. 
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Chapter Five: Improving the quality of drug research or simply 
increasing the cost?  
 
An evidence-based study of the cost for data monitoring in clinical trials 
 
Abstract 
Aim: Procedures for verification of data from clinical studies are intended to maintain 
reliability for clinical trial results. Guidelines or legislations relating to clinical data 
management are of limited value and no study has yet demonstrated its effectiveness. 
 
Method: Sponsor queries and dual entry procedures from one CRO on three different 
phase I trials are analyzed on content, impact and cost. 
 
Result: In this study, sponsor queries and dual entry procedures proved time and cost 
inefficient in detecting data discrepancies. 
 
Conclusion: We advocate a more evidence-based approach for enhancing data integrity 
throughout the process of clinical data management. 
 
Pronker, ES 
Geerts, BF 
Cohen, AF 
Pieterse, H 
 
BJCP (2011) 71:3; 467-470  
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5.1  Introduction 
 
The price of drugs has increased and consequently the pharmaceutical value chain has 
come under scrutiny 157. Drug pipelines are dwindling, leading to increasing cost for drug 
development 158, and patients are charged more for their medications 66, 71. Clinical phases 
of drug development require significant resources to assure patient safety and data 
integrity, the latter being endorsed by clinical data management departments (CDM) 66, 71. 
In view of the high investment in clinical development, CDM could be a suitable candidate 
for cost savings.  
 
Regulatory bodies have intensified administrative specifications for every process within 
clinical trials, aimed at preventing fraud and medical incidents 66. These developments are 
principally useful but have strongly added to the operational difficulties of performing 
clinical trials. International Organization for Standardization and International Conference 
on Harmonization documents only specify that data should be accurate, complete, legible 
and timely 159. With no instruction on how to attain or achieve this, trial organizers create 
individualized solutions. 
 
As a result, industry dogma defines how data integrity and quality can only be guaranteed 
through 100% data validation. The current best practice for assuring data integrity entails 
several procedures at each step of the study life cycle 160, including dual-data entry, 
external audits, regular external and internal monitoring, monitor queries, sponsor queries 
and governmental auditsA. Each audit and monitoring procedure applies similar data 
validation tools 161. 
 
In this study we examined the cost and potential efficacy of commonly used methods of 
assuring data integrity, focusing on sponsor queries and dual data entry methodologies. We 
argue that the sum of all procedures are costly and labour intensive, but may be excessive 
as the final objective is that trial results are reliable. We find that not all individual data 
points have to be correct, as randomization assures absence of bias. Moreover, there seems 
to be no distinction between trivial and critical issues, seeing that not all data points are 
equally important for statistical evaluation 162. We suggest an evidence-based approach to 
select actively critical parameters for assuring data integrity. 
 
5.2 Methodology 
 
First, we assessed the efficacy of the sponsor query procedureB. The study was performed 
at the Centre for Human Drug Research (CHDR), an academic oriented CRO with 
qualified personnel and clearly defined standards of operation (SOP) with an autonomous 
quality-assurance officer. For this analysis three phase I studies were selected, each having 
                                                          
A The innovation of direct data entry (recording the data directly into an electronic system, eliminating the use of 
paper CRFs) has not been taken into account in this research.  
B  There are three types of queries based on who identified the query: CRO internal queries, monitor queries and 
sponsor queries. Sponsor originated queries are the only formally recorded queries that are communicated from 
the sponsor back to the CRO. CRO internal queries or monitor queries are usually reported by word-of-mouth 
or e-mail. However a full accurate report of these types of queries is not available. 
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similar data processing routes, but differing in sponsors, number of participating 
volunteers, duration and time period in which they were performed. One thousand three 
hundred and ninety-five sponsor queries from the three studies were reviewed. 
 
Sponsor queries were assessed on two facets, keeping in mind that one query addresses 
one data point. A query was evaluated on content (scores are based on mutually exclusive 
categories, data point content, data point characteristic, query destination for answering, 
query topic and re-queries) and impact (scores are based on a five-question relative impact 
model, Table 5.1). All queries were scored by two arbiters in a double-blind fashion, and 
conflicting results were reviewed and resolved by an independent CDM consultant. 
 
The data were analyzed using statistical descriptives, followed by Fisher-exact and 
Pearson’s Chi-Squared to assess the relative association between categories. We studied 
associations between data point content parameters and the five impact questions 
individually, and refuted the null hypothesis each time. Second we reviewed the dual-data 
entry procedure. We used information on dual-entered study data as conducted at CHDR 
over the last 5 years in their trial database. Numerical data from first and second entry were 
compared and if a change was made on the second entry (assumed to indicate a discrepant 
first entry) the percentage difference between the two entries was recorded ignoring the 
positive or negative value. If a text value was changed during second entry the difference 
in number of characters was expressed as a percentage of the original entry. Ultimately; the 
cost involved was estimated based on a procedural flow-chart and real-time recording of 
activities at the CRO. 
 
5.3 Results 
 
5.3.1 Sponsor Query Assessment 
 
When assessing the query content parameter, 70% of queries addressed administrative 
qualities of the data point, for example an unclear checked box, whereas 12% of the 
queries addressed a medical data point. For query impact, 80% of the queries required a 
confirmation of the data point. The majority of the data points queried were related to a 
clinical endpoint (68%). There were only six queries (0.4% from 1395 queries and 0.001% 
of the combined 599,154 data points) that might have influenced the results of the clinical 
trials if the discrepancy had not been revealed. This leads to a number needed to treat of 
10,000 data points in order to find a possible significant error. The assessment was 
conservative as the six queries concerned a discrepancy in the coding of a non-serious 
adverse event. Five of the six queries were related to an administrative parameter but 
referred to a critical data point that could potentially influence the trial results.  
 
The cost of the sponsor-CRO query procedure cannot be accurately defined. However, if 
we assume that the handling of a single query by staff at the trial site and the sponsor takes 
about 1 h combined, the cost can be conservatively estimated at about €150. This means 
that for the three trials about €200,000 was spent for the correction of a minute amount of 
erroneous data. 
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Table 5.1 Impact of sponsor queries 
Table showing impact of sponsor queries based on the five question impact measure (per cent 
accurate to 2 decimal places); Impact Question 1 refers to whether the data point is adjusted as a 
direct consequence of the query. Impact Question 2 indicates whether the query challenges the 
credibility of the data point, by stating ‘please confirm’. Impact Question 3 refers to whether the data 
point queried is related to a clinical endpoint. Impact Question 4 refers to the empirical judgment of 
whether the data point has potential statistical impact on its specific parameter. Impact Question 5 
asks; would the discrepant data, if left unnoticed by the sponsor query, have any influence on the 
outcome of the clinical trial? Below Impact Question 5 is a description of the six sponsor queries that 
could potentially influence the statistics of the clinical trial 
 
PART A 
Question Frequency Percent/ % 
Impact Q1: Was data changed? 
No 1003 71.90 
Yes 392 28.10 
Impact Q2: Was confirmation asked for a data point?  
No 199 14.27 
Yes 1196 85.73 
Impact Q3: Did the query concern an endpoint? 
No 298 21.39 
Primary 570 40.92 
Secondary 382 27.42 
Other 143 10.27 
Impact Q4: Was the change significant for the specific data point? 
No 1326 95.05 
Yes 69 4.95 
Impact Q5: Could the change have changed the results of the trial? 
No 1389 99.57 
Yes 6 0.43 
 
PART B 
Impact Q5: Explained Sponsor Query 
A 
On the General Physical Examination Page a very long abnormality 
for psychiatric. Behaviour is recorded. This term is too long to enter 
on this page, therefore DE wrote a comment 
B The date and time performed should respect the theoretical time. Please verify and/or confirm 
C Actual does should be equal to planned dose. Please correct 
D First inhalation of product has a comment, indicating that a leak existed, but full actual dose is reported. Please correct or explain. 
E The estimated date is prior to the demography date. Please clarify 
F 
An AE even took place, and is recorded with action taken C.O. The 
corresponding CNP page is empty. Please provide 
treatment/procedures with relevant information to be recorded on the 
CNP, or verify that the action O can be removed for the AE. 
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5.3.2 The Dual Data-Entry Procedure 
 
We evaluated the efficacy of this procedure to detect significant errors that might influence 
the outcome or conclusions of a trial (Table 5.2).Of the total number of dual entries (n = 
1,605,682) 1.8% were changed during dual entry and the average change amounted to 
156% of the primary entered original value. The magnitude of most of these changes was 
within 0–150%, with outliers of over 500% (Figure 5.1). The parameters tested were 
measured at least on 10 occasions in at least 10 studies.  
 
Table 5.2 CHDR database inspection of single and dual entry.  
The table shows the descriptive results of the data points changed after dual entry. % value is 
accurate to two decimal places. 
 
 Number of data points Percent (%) 
Total number of data points 2,806,797 - 
Single Entry 1,230,738 - 
Dual Entry 1,576,059 - 
Number changed after Single Entry 22,533 1.83 
% Change - 155.80 
Number changed after Dual Entry 1242 5.50 
 
If these changes were all in one direction this would lead to a maximum theoretical 
difference in the average value of a data set of 1.7% compared with the situation in which 
the errors were not detected. The probability of such a difference leading to an important 
change in statistical inference is low in view of the normal variability in biological data 
that generally exceeds 10%. 
 
Dual entry of this number of data points (assuming 10 seconds per entry) approximately 
requires 2 man years at an all inclusive cost of approximately €200,000. 
 
5.4 Discussion 
 
Clinical trials are essential for evaluation of many interventions in health care making 
quality data indispensable. During the evolution of the pharmaceutical value chain, 
procedures have been added 163. We have demonstrated that traditional procedures need to 
be evaluated continuously to assure that they are cost effective. By performing this 
evidence-based audit we have demonstrated the resources involved with generating and 
solving sponsor queries. Additionally, we estimated the cost savings to be considerable, 
excluding knock-on effects on travel expenses and infrastructure. 
 
To reduce CDM cost we propose small procedural alterations. First direct data-entry could 
replace dual-data entry. Second, sponsors could review queries before blindly sending 
them to the CRO, filtering out queries that relate to self-evident checks. This can be 
accomplished through updating the trial validation plan and strategy. Third, 
communication between sponsor and CRO could be improved to implement a feedback 
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system on query type that allows for a learning curve; fewer sponsor queries nearer trial 
completion. Furthermore, giving more attention to the initial planning phases of a study 
may also affect data quality at later stages. 
 
Last, we advocate a more evidence-based approach to clinical data management using the 
concept of ‘resilience’, the degree of flexibility for data point error. Currently there is no 
assessment to identify high risk data points that, if discrepant, could influence the results 
and consequently the conclusions drawn from a trial. We hypothesize that it is possible to 
pre-select these susceptible data points based on two criteria: its relation to a clinical 
endpoint and its flexibility for being discrepant. The latter criterion can be forecast using 
power-based calculations to identify high risk data points (P = 0.95 for example), that have 
the potential to influence the statistics if discrepant. This will reduce the resources 
involved as instigated by industry dogma and increase CDM efficiency. 
 
Figure 5.1 Histogram showing magnitude of differences between first and second data 
entry 
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5.4.1 Considerations 
 
Several restrictions apply to this study. First, the sample consisted of only three studies. 
Although selection was actively performed to prevent structural bias and spread the 
variables, it was only a small sample compared with the hundreds of drug trials performed 
on a global scale. Additionally, the extremely low detection rate of erroneous values may 
not be representative for other situations. They were obtained in a GCP-regulated and 
professionally staffed unit, making error rates (and also cost per error) quite different from 
other environments. The value of different quality assurance procedures therefore might be 
tested for that particular environment. Our data and methodology may assist with this. 
 
This article presents the first empirical study on the topic of sponsor queries and the CDM 
system. This pilot study can benefit scientific organizations and pharmaceutical companies 
by starting to rethink the concept of data validation and current procedures to achieve this. 
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Chapter Six: Scratching the Surface 
 
Exploratory Sector Level Analysis of Key Opinion Leaders on Novel 
Adjuvanted-Vaccine Development  
 
Abstract 
Chapter 6 offers an exploratory view on the potentially rate-limiting factors encountered 
during adjuvanted-vaccine development that affect value chain dynamics. Adjuvants are 
considered immunostimulating substances that can be added to a vaccine. Although 
adjuvants have the potential to elicit adverse reactions, they also offer certain benefits 
including; increasing the immune response in senescent population groups and dose-
sparing properties. Nevertheless, after approximately 90 years of R&D, we question 
ourselves why only four adjuvants have been approved for use in human vaccines? 
Although ample literature is available describing the main risks for developing adjuvanted-
vaccine candidates, it remains unclear as to how these potentially rate-limiting factors 
compare and interact. Key opinion leaders in the field of adjuvanted-vaccine development 
were approached in order to collect a unique qualitative empirical dataset 
 
Pronker, ES 
Weenen, TC 
Commandeur, HR 
Claassen, E 
Osterhaus, ADME  
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6.1 Introduction 
 
Vaccines are considered to be the most effective medical intervention in controlling the 
spread of infectious diseases for the benefit of public health 59. Met with severe opposition 
at the start of their introduction in the 19th century 48, Edward Jenner’s experiments led to 
the single greatest accomplishment in medical history: global eradication of smallpox by 
197959. Although vaccination campaigns today are still facing an anti-movement 164, the 
vaccine industry has fruitfully produced prophylactic and therapeutic solutions for over 25 
human infectious diseases 21. Additionally the industry is yielding blockbuster products, 
including Wyeth’s Prevnar® and Merck’s Gardasil® both reaching annual sales over US $ 
1 Billion 165. Representing a solid 2% within the pharmaceutical framework, the value of 
the vaccine industry is predicted to surpass the US $ 30 Billion mark by 2015 55. 
Furthermore, the vaccine industry is realizing an astounding compound annual growth rate 
(CAGRA) of 5.5%, compared to a mere 0.3% for new chemical entities (NCE) 166-168. With 
such prospects, vaccines will inevitably continue to be a part of the future. 
 
Unfortunately, since the last decade the biopharmaceutical industry has been experiencing 
a so-called productivity gap 169. This concept delineates the situation whereby the 
proportion of consumed resources exceeds the expected turnover 170, 171. It results in an 
insufficient amount of new product launches to sustain current business models and satisfy 
unmet medical needs 172, 173. This phenomenon also holds true for the vaccine industry 174, 
mainly due to the intensifying regulatory environment, escalating research and 
development (R&D) costs, and improved best-standards of care 57, 99, 175. Nevertheless, by 
staying innovative, vaccine manufacturers will be able to maintain their competitive niche 
and continue to accommodate the unmet medical needs of public health. 
 
Vaccine R&D strategies have evolved from the basic isolate-inactivate-inject paradigm 176 
to a multidisciplinary exercise 177. The first generation classical vaccine antigen 
preparations for infectious diseases include inactivated (e.g. influenza virus) and live-
attenuated methodologies (e.g. measles virus) 178-180. However, these techniques are not 
feasible for all types of pathogens, creating a need for novel approaches in order to target 
the more complex unmet infectious diseases. Newer strategies of pathogen inactivation 
include more sophisticated recombinant preparations for example (e.g. Hepatitis B Virus 
(HBV), Human Papilloma Virus (HPV)) 179, 180. Unfortunately, these newer methods 
generally do not elicit sufficiently large immune responses, making the addition of an 
adjuvant necessary 52, 55, 181.   
 
Adjuvants are approved in combination with the specific vaccine antigen (Appendix A). 
To-date: four adjuvant compounds for use in human vaccines have received market 
authorization by the European competent authority, namely; Aluminium salts (Alum) in 
1920, Novartis’ MF59 in 1997, GlaxoSmithKline’s (GSK) AS04 in 2005 and AS03 in 
2008 182. The American Food and Drug Administration (FDA) approved two adjuvants - 
Alum and GSK’s AS04 in 2009 183 - and approval is currently pending for GSK AS03 184. 
Evidently, access to adjuvanted-vaccines is restricted to the regions governed by the 
                                                          
A CAGR: Compound Annual Growth Rate, represents the period between 2009 to 2014 166 
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competent authority, making those vaccines unavailable to patients in other locations. This 
does not imply that these are the only adjuvant candidates or that initiatives are limited to 
one continent. In fact, multiple projects are ongoing at locations worldwide 52, 182, 185-192 and 
a compendium lists over 90 possible candidate adjuvants 193. Nevertheless, after 
approximately 90 years of R&D we question ourselves why there are so few approved 
candidates for use in human vaccines targeting infectious diseases.  
 
Our objective is to uncover rate-limiting factors (RLF) encountered during the adjuvanted-
vaccine value chainA as experienced by experts in the field of adjuvant R&D. Based on the 
principal-agent theory (PAT), we believe a conflict of interests between the internal 
perceptions of key opinion leaders (KOL) on the challenges faced contribute to the low 
approval rate of novel adjuvant compounds. Experts interviewed represent the golden 
triad; knowledge institutes, industry, and regulatory and public health authorities 
(R/PHA)B. Opinions are quantified through a weighted-ranking exercise, in order to 
measure the variance between KOL responses. The present exploratory analysis offers 
previously unpublished and practical insights on the topic.  
 
6.2 Conceptual Framework 
 
The principal-agent theory (PAT) offers a framework for investigating opinions of KOLs 
on RLFs in the adjuvanted-vaccine value chain. Originating from theories on risk-sharing, 
PAT has evolved in the last four decades into a widely applicable and resilient socio-
economic tool 194, 195. First described by Jensen in 1976 196, the fundamentals of PAT 
include a symbolic contractual relationship between two autonomous, non-competitive 
parties. In short; the principal delegates the agent to commit to activities, whereby the 
agent incurs costs in the process, in order to develop services and/or commodities on 
behalf of the interests of the principal. Based on this definition, the R/PHA is taken as the 
principal, and the KOLS representing the knowledge institutes and industry as the agents 
(Figure 6.1). 
 
Nevertheless this dyadic social interaction is influenced by four main factors; information, 
risk, external environment and self-interest. The aspects of information asymmetry, risk 
management strategies (as covered by the prospect theory for example 197) and effect of 
contextual factors on decision making fall beyond the scope of this discussion. Focussing 
on the internal preferences of each party, the system is said to experience an agency 
problem if these do not align. The subsequent conflicts of interests may lead the principal 
and the agent to adopt inaccurate beliefs, approve ineffective strategies and develop a 
general distrust towards each other 198. Under these circumstances the principal can resort 
to increased monitoring of the agent, whereas the agent might create a demand for services 
against the principal’s interests 199. 
                                                          
A  Value chain; consists of internationally regulated R&D phases, in chronological summary; discovery, pre-
clinical and toxicity screening, human clinical trials, regulatory approval and post-marketing surveillance. 
B  Knowledge institution; non-profit seeking researchers, mostly involved with discovery phases up to human 
clinical phase I/II of the value chain. Industry; profit-seeking companies. Regulatory/PHA; non-profit 
governmental and non-governmental organizations involved with regulating adjuvant R&D and market 
approval decisions. 
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Figure 6.1 Principal and agent relationships in supply-driven adjuvanted-vaccine value 
chain 
 
 
 
In adjuvanted-vaccine development, the principal and agents are connected in a supply-
driven value chain configuration 200. Although the industry primarily holds the burden of 
proof for safety, efficacy, quality and ethics, it is the interaction with the knowledge 
institutions and regulatory field that is required for successful adjuvanted-vaccine 
commercialization. As the knowledge institutes and the industry actively engage in 
technology and knowledge creation - specific and integrative respectively - the information 
asymmetry favours the agents. Moreover, information exchange from knowledge institutes 
to industry takes place in the form of technology transfer, and vice-versa through 
outsourcing 201. 
 
In terms of self-interest, literature descriptively indicates each actor’s predispositions, 
though limited in comparison. To start off with the principal: the R/PHA mitigate the 
interest of the patient population 52, 182. Adjuvants - from the regulator’s perspective - are 
mysterious NCEs without an EPHMRAA classification code. Furthermore, it remains 
ambiguous whether adjuvants are classified as an excipient or active compound B. 
Demonstrating their potential for inducing severe side-effects (for example Freund’s 
Adjuvant resulting in tissue damage 185), adjuvant compounds are considered extremely 
potent substances to be approached vigilantly 202. As a result, R/PHAs have discontinued 
the market authorizations for vaccines, based on suggested correlation between the 
adjuvant compound and certain side-effects. Examples in Europe include; Berna Biotech’s 
                                                          
A  EPhMRA: European Pharmaceutical Marketing Research Association for the Anatomical Classification of 
Pharmaceutical Products  
B  Knowledge Institute representative  
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NasalFlu® containing Escherigan adjuvant in 2001 due to alleged causation with Bell’s 
palsy 203-205, Microgen’s Grippol® containing polyoxidonium adjuvant due to basic allergic 
events in 2006 206-209, and most recently the restricted use of GSK Pandemrix® containing 
AS03 adjuvant, which is pending additional research into the suspected correlation with 
narcolepsy in Scandinavian countries in 2010 210.  
 
On the other hand, the general attitude of the agents towards adjuvants is described in the 
literature as more favourable. Both knowledge institutes and industry acknowledge the 
potential of an adjuvant to enhance the immune response, even with reduced antigen 
concentration in the vaccine. Nevertheless, publications also highlight the drawbacks; 
restricted international collaboration due to a lack of suitable comparators 211 and the 
return-of-investment is estimated to be negligible 52, 188. An example of a firm voluntarily 
revoking a market authorized adjuvanted-vaccine is Sanofi Pasteur’s Humenza® 
containing AF03 adjuvant in 2011, due to commercial reasons 212, 213. 
 
This research supplements the already existing body of literature with a quantitative 
comparison of the internal-preferences. Opinions on RLFs are considered to reflect self-
interest, which is believed to be distinct for the three groups of KOLs involved in adjuvant 
R&D. By measuring the perceptions on RLFs, we intend to uncover proximities between 
the internal-preferences of each KOL. The resulting exploratory evaluation of PAT could 
provide novel insights for the adjuvanted-vaccine development community. 
 
6.3 Methodology 
 
We define RLFs as elements encountered throughout the vaccine value chain, potentially 
delaying procedures towards the ultimate goal of successful commercialization. Evidently, 
each adjuvant is developed under a unique set of circumstances, yet there are certain 
universal factors that influence the survival of all adjuvant projects 182, 214. By recognizing 
in the literature that certain core factors occur in distinctive phases of the value chain, a 
framework was designed to accommodate for this (Figure 6.2; Appendix B). Validated in 
three pilot interview sessions prior to implementation; this framework forms the back-bone 
to the 60 minute semi-structured interviewsA. Furthermore, experts were selected using the 
snow-ball method, allowing it to progress for three generations in order to reduce selection 
bias 215. 
 
Based on the framework, KOLs were asked to complete a weighted-ranking exercise. 
Weighted-ranking is a tool used to quantify the opinions on a set of pre-determined 
elements by capturing the associations between core factors and the degree they are 
assessed as rate-limiting 216, 217. It allows experts to quantitatively indicate their perceived 
magnitude on the influence of particular RLFs. KOLs were asked to rank their personal 
top-ten list of RLFs and indicate its weight by distributing 100 points over the ten factors 
selected. Relative weighted ranks were calculated for each RLF per respondent (ݔ) using 
the formula on page 60. Subsequently the relative weighted ranks were aggregated 
according to the three KOL groups.  
                                                          
A Interview tool available upon request 
 60 
ܴܮܨ ܴ݈݁ܽݐ݅ݒ݁ ܹ݁݅݃ℎݐ݁݀ ܴܽ݊݇௫ = 
 
൭ቆ(11 − ܴܽ݊݇௫)11 ቇ ∗ 100൱ ∗ ൭ቆ
(ܹ݁݅݃ℎݐ௫)
∑ ܶ݋݌ 10 ܴܮܨ ܹ݁݅݃ℎݐቇ ∗ 100൱ 
 
The weighted and ranked top-ten list generated is headed by those factors that have the 
greatest influence to the continuation of the value chain. Consequently, factors ranked 
lower down the list remain essential to success, however are considered to have an 
attenuated impact on the overall outcome of the value chain. The results were 
supplemented by a univariate ANOVA for the statistical variance between the perceptions 
of each KOL group. 
 
In order to uncover underlying reasons for the differences in opinions, interview transcripts 
are analyzed according to the grounded theory 218. Open-axial coding was completed by 
three researchers in double-blind design, employing Atlas.ti software © 219. The resulting 
axial-codes were organized into a visual network by linking associations between the 
phenomena. This overview allows for the identification of key concepts that offer 
explanations for the different self-interests between the principal and agents.  
 
Figure 6.2  Value Chain Framework (c) RLFs categorized according to their sphere of 
influence 142, 172, 182, 214, 220, 221. 
Reg.  Regulatory approval of the adjuvanted-vaccine 
RLF Rate limiting factor 
 
Preclinical PhaseDiscovery Phase Clinical Phase I-III Post-Marketing SurveillanceIND CTD
Vaccine Value Chain
Post-MarketingProcess
Process RLF Post-Marketing RLF
Biomarkers Commercial
Communication Education
Cost of Goods and Upscaling Liability 
Efficacy Post-Marketing Surveillance 
Regulations Price 
Feasibility Reimbursement 
Formulatability
Intellectual Property
Quality
Safety
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6.4 Results and Analysis 
 
27 KOLs voluntarily participatedA, of which 6 represent the knowledge institutionsB, 12 
the industryC and 9 are R/PHA officialsD. To start off with, KOLs were prompted with the 
framework and invited to comment on the list of potentially RLFs as well as their location 
within the framework. Saturation is achieved soon after the pilot interviews (Figure 6.3). 
Only respondent 18 - of R/PHA origin - introduced a novel factor of vaccine 
administration. Nevertheless, the magnitude for this additional factor is not perceived as 
significant enough by other experts to appear in the final outcome of the weighted ranking 
exercise. It is therefore assumed the framework reflects the 20 most important potential 
RLFs for novel adjuvant R&D according to the KOLs. 
 
Figure 6.3 Saturation curves of the rate-limiting factors in the framework.  
Blank markersE indicate respondents unable to complete the weighted ranking  
 
 
 
  
                                                          
A  All interviews are completed within a period of 4 months to ensure consistency of interview technique 
B  Knowledge Institutions represented by; Vrije Universiteit Amsterdam, the Netherlands; Erasmus University 
Rotterdam, The Netherlands; Glasgow University, United Kingdom; University of Groningen, The 
Netherlands; University of Lausanne, Switzerland. 
C  Industry represented by; Litevax BV; Intervet/Schering-Plough Animal Health and Intervet International; 
Abbott Biologicals BV; Brenntag-Nordic; Novartis Vaccines & Diagnostics; Merck; Crucell BV; CSL Limited; 
GSK Biologics; Sanofi Pasteur; Biomedical Primate research centre, the Netherlands; Staten Serum Institute, 
Denmark 
D  Regulatory/ PHA represented by; European Commission; European Vaccine Initiative; European Adjuvant 
Advisory Committee; Medical Ethics Board the Netherlands; Ministry of Public Health Belgium (FAGG); 
Ministry Public Health the Netherlands (RIVM/NVI) 
E  Non-respondents are equally distributed amongst the three KOL groups; 1 representing the Knowledge 
Institute, 1 representing the R/PHA, and 3 representing the Industry. 
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6.4.1 Weighted Ranking  
 
Results indicate a significant internal validity of KOL group responses (Figure 6.4). 
Additionally, the ANOVA analysis revealed no significant effect between the weighted 
ranking values and KOL group membership (Table 6.1). However, the weighted ranking 
responses are significantly dependent on the RLF itself.  
 
Figure 6.4 Weighted-ranking, ordered according to all results. Standard deviations 
indicated. 
PMS Post Marketing Surveillance 
CoG Cost of goods and up scaling 
R/PHA Regulatory and Public Health Authority 
 
 
 
By mapping the factors in a decision matrix configuration, similarities and difference 
between KOL responses are visualized (Figure 6.5). The top-ten of the principal’s opinion 
is taken as a reference, to which the responses of the agents are compared. Starting with 
the similarities; all KOLs unanimously position safety and efficacy in first and second 
place respectively. Differences in opinions are evident from the third position onwards, of 
which quality, regulatory, cost of goods (CoG), intellectual property (IP) and commercial 
RLFs are selected for further clarification. 
  
Safety (Rank 1) 
Efficacy (Rank 2)
Quality (Rank 3) 
CoG (Rank 4) 
Regulatory (Rank 5) 
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Communication (Rank 7) 
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6.4.1.1 Safety 
 
Safety has a dichotomous impact on the value chain. As one expert summarizes; “At the 
end of the day, we need to separate safety from the image of safetyA.” Indeed, many KOLs 
are confronted by the prejudice that adjuvants in a vaccine system imply safety concernsB, 
when it is rarely the determining factor that would stop adjuvanted-vaccine developmentC. 
Safety, by itself, refers to the actual indicators of the item, whereas the image of safety 
deals with the interpretation of the data. 
 
Establishing safety takes place at every stage of the value chain. It is an assessment of the 
physical side-effects from administering the adjuvanted-vaccine, and forecasting the 
probability of developing the predicted acute and/or chronic manifestations. Measuring 
safety is a meticulous exercise, whereby the outcome is dependent on the antigen-adjuvant 
combination and related to the animal model. Moreover, results of the preclinical phase are 
not predictive for the effect in human clinical trials, which in turn does not project adverse 
reactions in the post-marketing phase. Consequently, establishing causality between the 
side-effects and the various components of the vaccine-complex remains challenging.  
 
The second aspect - implicating the interpretation of the safety data - is usually 
accomplished using a risk-benefit ratio. Determining the thresholds within which the risk 
of developing certain side effects are tolerated against the benefits of administering the 
prophylactic vaccine versus an alternative intervention is an arbitrary task, specific to each 
class of KOL. The perception is influenced by; the current standard of treatment, scale of 
the disease burden, severity of disease pathogenesis, demographics of the target population 
and whether the vaccine is prophylactic or therapeutic. Interviews reveal that each class of 
KOL is unaware of the limits set by the other groups, although the image of safety is 
decisive in the current market spaceD. As a result, safety is regarded by all KOLs as the 
least resilient of the rate-limiting factors, with potentially the largest impact on the 
continuation of adjuvant R&D. 
 
6.4.1.2 Efficacy 
 
Efficacy is the second highest rated factor. In a purely practical sense, an effective 
adjuvant can be developed without it being safe - whether it will be included in a vaccine 
is something elseE. Additionally, there is also no point in continuing development if the 
adjuvant is not effective: “There are a couple of cases where this happened, but eventually 
you will have to own upF.” Efficacy data justifies the inclusion of the adjuvant in the 
vaccine, and it can best be divided into protective efficacy and immunogenicityG.  
                                                          
A Knowledge Institute representative 
B Regulator and PHA representative 
C Knowledge Institute representative 
D Industry representative 
E Industry representative 
F Industry representative 
G Regulator and PHA representative 
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Protective efficacy describes the complete clearance of the pathogen and the ability of the 
adjuvanted-vaccine to prevent disease latency. In the clinical setting, protective efficacy 
can be established by comparing the adjuvanted-vaccine with the current best practice in 
healthcare, demonstrating either non-inferiority or superiority. Nevertheless, efficacy can't 
always be measured accurately during clinical development. Several interview respondents 
believe that protective efficacy within a population is best established once the adjuvanted-
vaccine has been brought onto the marketA.  
 
Immunogenicity expresses whether the adjuvanted-vaccine has immunogenic properties. A 
measure for this aspect of efficacy includes the correlate of protection, which is a physical 
indication of the individual’s immune response 222. In general; infectious diseases for 
which vaccines are currently available have established correlates of protection. For 
example seasonal influenza vaccines, whereby target levels of antibody titres are predictive 
for sero- and clinical-protection 223. Most other diseases do not have accepted correlates of 
protection, such as HIV/AIDS for example 224. In the case of the latter scenario, a situation 
is created whereby multiple working definitions of immunogenicity for the same infectious 
disease co-exist. Combined with the sentiment research teams hold for their own projects, 
it contributes to the general conviction that “one man’s adjuvant is another’s accident 
waiting to happenB.” It evokes a cautious attitude during the development of an 
adjuvanted-vaccine. All reasons combined; this factor is considered to have low threshold 
beyond which it will be interpreted as rate-limiting. 
 
Table 6.1 ANOVA results  
PMS Post Marketing Surveillance 
 
Ranking order Principal Source df F Sig.  p-value 
1 Safety 2 .700 .509 
2 Efficacy 2 .263 .771 
3 Quality 2 1.649 .236 
4 Regulatory 2 .965 .414 
5 Education 2 .559 .595 
6 PMS 2 .210 .816 
7 Feasibility 2 1.400 .346 
8 Formulatability 2 .455 .658 
9 Liability 1 N.A. N.A. 
10 Communication 2 ,724 .514 
- RLF 10 8.378 .000 
- KOL group 2 .145 .865 
- KOL group * RLF 20 .513 .956 
 
  
                                                          
A Industry representative 
B Knowledge Institute representative 
 65 
6.4.1.3 Quality 
 
Quality is prioritized in third place by both the knowledge institute and R/PHA KOLs and 
in eighth place by industry representatives. From the perspective of the knowledge 
institutes, quality is experienced as a rate limiting factor specifically during valorization 
activities. Most academic research environments do not match the stringently regulated 
industrial setting. Quality is therefore experienced as limiting technology transfer 
opportunitiesA.  
 
The R/PHA representatives are also of the opinion that quality is imperative at every stage 
of the value chain, equating it with safety. Quality is multi-disciplinary, and includes 
monitoring different R&D aspects, including but not limited to; quality of ingredients, 
batch consistency and data management. As quality relates to essentially all R&D 
activities, it permits low margins for error. 
 
As described by experts representing the industry, quality is an essential aspect in adjuvant 
R&D but it is not necessarily a high ranking RLF. Quality is viewed as inherent to the 
process of adjuvant R&D, since product development requires compliance with good 
manufacturing practices and other legislationsB. It is a secondary effect that could turn 
quality into a rate-limiting factor, namely the considerable cost associated with it. 
Consequently this is reflected in the results, as Industry KOLs have ranked CoG in third 
place (Section 6.4.1.5). 
 
6.4.1.4 Regulatory 
 
Any argument relating to the regulatory environment as a RLF comes in at fourth position 
for both the R/PHA and industry KOLs. Adjuvanted-vaccine development is regulated at 
national, international and global (ICHC/ISOD) levels, through hardE and softF legislature. 
According to both agents, the regulations are often experienced as suggestive. 
Nevertheless, the R/PHAs attempt to create a balance between formulating generalized 
legislation that is too difficult to comply with, and passing lenient measures that would 
automatically approve adjuvant compounds without R/PHA consentG.  
 
From the perspective of the industry KOLs, there are two main reasons for the high 
weighted-rank. First, an adjuvant is never approved for market entry as a single entity but 
as a component in the vaccine system. Nevertheless, novel adjuvant compounds 
                                                          
A  Knowledge Institute representative 
B  Industry representative 
C  International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) 
D  International Organization for Standardization (ISO) 
E  Hard regulations include completing certain documents in the adjuvanted-vaccine dossier, for example 
F  Soft regulations offer guidance to the interpretation of the hard regulations  
G  Industry representative 
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considered for inclusion require sufficient proof of safety, efficacy and qualityA. Especially 
with novel adjuvant innovations, the assessment concerning sufficient proof by the R/PHA 
officials remains unclear to industry representativesB.  
 
Second; the financial consequences for some of the R/PHA inquiries concerning the 
ajduvanted-vaccine dossier. For example when the R/PHA official alludes to the 
correlation between the adjuvanted-vaccine and the probability of developing an auto-
immune disease. In principal this is a purely theoretical concept, as the cause for most 
auto-immune diseases remains unknownC. Due to experimental practicalities, the only 
remaining option for the manufacturer would be to monitor the adjuvanted-vaccine closely 
in resource intensive, long-term observational studies. Depending on the sponsor, R&D 
activities could be suspended following this R/PHA decision. 
 
Figure 6.5 Matrix showing top-10 rate-limiting factors. The order generated by the 
principal (R/PHA) is taken as a reference, to which the behaviour of the curves 
representing the agents’ internal preference is compared. 
PMS Post Marketing Surveillance 
R/PHA Regulatory and Public Health Authority 
 
 
 
                                                          
A  Regulator and PHA representative 
B  Industry representative 
C  Knowledge institute representative 
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6.4.1.5 Cost of Goods and Up Scaling 
 
The cost of goods and up scaling is considered by the R/PHA KOLs as insignificant. In 
fact, all interviewees agree that the R/PHA should remain blind to this aspect in order to 
maintain their focus on assessing health benefits. However, the R/PHA advocate that if 
knowledge and technology on up-scaling is available, to include it in the dossier at the 
earliest possible development stage. Ranking at fifth place, the knowledge institute KOLs 
realize the financial context of adjuvant development and envision this as a practical RLF. 
For the industry KOLs, this RLF is ranked in third place and is closely associated with 
feasibility. Up scaling is considered a part of the business case and should result in the 
final adjuvanted-vaccine product to enter the market at a competitive price.  
 
6.4.1.6 Intellectual Property 
 
To the industry KOLs, intellectual property (IP) is perceived as significant enough to rank 
in 7th place. For the industry representatives patents are seen as an inevitable commodity, 
essential in advancing product development. Nevertheless, specific unpatentable in-house 
knowledge is required for manufacturing the adjuvant; “I can give you all the ingredients 
for an apple-pie, but we would both make two completely different cakesA.” In fact, 
patents are only considered to be rate-limiting if the vaccine requires the patented adjuvant 
from a third party and the license is unattainable. 
 
Both R/PHA and knowledge institute representatives are aware of the necessity for IP 
protection in advancing commercial activities. Even though R/PHA officials are not 
involved with IP, an increasing number of knowledge institutes have established 
technology transfer offices and stimulate patent application. Nevertheless, it is highly 
unusual for a product to be developed beyond the pre-clinical stages by a university. In the 
knowledge institute setting, the patent itself is often regarded as the final productB. 
 
6.4.1.7 Commercial 
 
Commercial relates to the channels required for distributing the adjuvanted-vaccine to the 
end consumer. For the industry representatives in particular, the commercial element is 
taken into consideration prior to developing the adjuvanted-vaccine. For example; 
designing a product for the economically developing countries where the access to cold-
chain and last-mile logistics could influence R&D strategies. Most interviewed KOLs also 
recognize the significance of pre-existing public and private distribution channels, and the 
possibilities for creating a new channel if it is not available.  
 
6.4.2 Self-Interest 
 
The 27 interview transcripts were analyzed in order to gain insight into the underlying 
social constructs influencing KOL self-interest. By applying the grounded theory, the 
                                                          
A Industry representative 
B Knowledge Institute representative 
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content analysis resulted in 1118 open codes which were subsequently categorized into 57 
axial codes. Through linking the main associations and directional relationships between 
the axial codes, an overview is created revealing the main social constructs (Figure 6.6). 
As derived from the interviews, the foundation for the KOLs’ perspective on adjuvanted-
vaccines encompasses four main concepts; risk management, innovation strategy, 
valuation and funding.  
 
6.4.2.1 Risk Management 
 
Although falling beyond the scope of this analysis, risk management strategies essentially 
influence the internal-preferences of the KOLs on adjuvanted-vaccines. The interview 
analysis reflects several items that could influence the perception of risk, including; 
historical precedents (e.g. track record, collective memory), culture (e.g. bias for success, 
corporate culture, perception of failure) and advocacy between actors (e.g. networking and 
social strategy). Especially actor advocacy and the relationship dynamics between the main 
actors seem to be influenced by the social construct of responsibilityA. With regard to the 
perceived risk for developing and commercializing an adjuvanted-vaccine, responsibility 
stimulates the discussion concerning the proportional allocation of reward and liability 
between the actors. Risk management affects, and is simultaneously affected by, 
innovation strategies and funding.   
 
6.4.2.2 Innovation Strategy 
 
In the pharmaceutical market, economic growth is generally based on incremental 
innovation, although radical innovations are considered more valuable 225. Nevertheless, as 
described by most KOLS, the caveat with radical innovation is the barrier to the social 
recognition and acceptance of novelties 226. The figure lists various items specific to 
adjuvanted-vaccine development for which social acceptance and recognition are 
challenged. Ultimately, the perception of each KOL on the value of innovations forms the 
basis to innovation strategies, which in turn influences risk management decisions.  
 
6.4.2.3 Valuation 
 
Valuation is broadly defined to encompass individual-, organizational- and societal-level 
perception on the benefit of the adjuvanted-vaccine in both economic and social values. 
Essentially it is the valuation process that fuels the conflict-of-interest between the 
principal and agents. Based on the interview transcripts, the perceived value of an 
adjuvanted-vaccine is influenced by; contextual factors, epidemiological data, the value 
chain and the market landscape. Consequently, each KOL group has their own 
interpretation of those four features, which leads to different conclusions regarding the 
priority for adjuvanted-vaccine R&D projects. As a result of the different agendas, the 
agents might not target an infectious disease area as prioritized by the principal. This leads 
to the creation of specific tax-breaks or subsidies in order to financially stimulate the 
agents in a certain R&D direction.   
                                                          
A Responsibility is viewed in terms of reward and liability 
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6.4.2.4 Funding 
 
This final pillar is the financial reflection on KOL valuation and risk management 
perspectives associated with adjuvanted-vaccine R&D. Funding entails a practical 
assessment of the income (for example investment from altruistic foundations), the 
operational costs (for example CoG) and return-on-investment (for example willingness-
to-pay). According to the majority of KOLs, the cost for the adjuvant R&D can only be 
recovered after significant timelines.  
 
Figure 6.6 Grounded Theory system analysis of the axial codes 
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6.5 Discussion 
 
In the view that global society is threatened by numerous unmet medical needs that require 
appropriate prophylactic vaccination campaigns, innovative solutions are sought in order 
to address those pressing issues. Such measures include, but are not limited to, adjuvants. 
Adjuvants prove indispensible in the future of effective human vaccine development, yet 
add a degree of uncertainty to the already risk intensive vaccine value chain. Additionally, 
the benefits for including adjuvant compounds in a vaccine outweigh the opposing 
arguments.  
 
This exploratory study merely uncovers the tip-of-the iceberg when it comes to revealing 
the challenges faced during adjuvanted-vaccine development. The data presents a snap-
shot of the current situation by quantitatively comparing opinions of experts active within 
the field of adjuvant R&D. Nevertheless, several KOLs were unable to complete the 
exercise. The main argument is related to the interconnectedness of the factors, whereby 
any issue regarding a particular RLF could produce a knock-on effect throughout the value 
chain. In other words; all RLFs are equally important for the outcome of the whole 
process. Indeed the framework presents an over-simplified version of the value chain, 
revealing only the core RLFs. For the purpose of this exploratory study, the framework 
attains it’s goal in providing a validated starting point for further research into the topic.  
 
Additionally, plotting the weighted-ranking results in a matrix configuration proves a 
valuable method for measuring the internal-preference component of PAT and 
subsequently visualizing the similarities and differences. Based on the internal-
preferences, adjuvant R&D is diagnosed with a partial agency problem. Partial in the sense 
that on the one hand the weighted-ranking data reflecting the KOLs internal preference 
only overlaps with regard to two RLFs. The remaining RLFs indicate the topics which 
potentially fuel the conflict-of-interests. On the other hand, several adjuvanted-vaccines 
have recently been awarded market entry by the European competent authorities. Although 
the topics contributing to the conflicts-of-interest between the internal-preferences of the 
principal and agents have been identified, a comprehensive understanding of the agency-
problem entails further research into the knowledge symmetry, risk and external 
environment.  
 
Content analysis of the interview transcripts reveals four interlinked social constructs that 
could clarify the conflicting internal-preferences. Namely attitudes towards risk 
management, innovation strategy, valuation and funding are found to cause the differences. 
In the view that perceiving a factor as rate-limiting is largely depended on the self-interest 
of the KOL, further research on the topic of social constructs is suggested. Such data could 
have practical implications for promoting consensus between the KOLs regarding critical 
RLFs, as well as determining the resiliency on the corresponding acceptable thresholds. 
 
This study was designed to explore the topic of rate-limiting factors, and not intended to 
solve the issues encountered during adjuvanted-vaccine development. In light of the 
observations, we would question whether a universal order of RLFs can be attained, and 
whether this will facilitate successful commercialization of novel adjuvanted-vaccines in 
the future. Moreover, in the view that the majority of vaccine candidates never attain 
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market registration 172, 174, we would advocate more transparency on reasons for project 
discontinuation. At the end of the day; sharing lessons learned from failed attempts could 
prove valuable for advancing the field of vaccinology, in order to win the infectious 
disease battle for the benefit of public health.   
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6.6 Appendix A 
 
Depending on the infectious pathogen and the preparation technique some antigens are not 
immunogenic enough, which is when adding an adjuvant to the vaccine complex is 
beneficial 227. The term adjuvant is derived from the latin word for help - adjuvare 52. It 
embodies the functionality of the adjuvant compounds: substances that guide the immune 
system more efficiently, either through a slow-release depot mechanism or facilitating 
antigen recognition 192.  
 
As a science, it is based on the observation that certain substances exasperate the immune 
system 228-230. This inherent immunomodulating attribute creates a catch-22 situation: it is 
what makes the adjuvants potent, but is simultaneously the property that causes the 
(serious) adverse reactions 231. Furthermore, the precise mode of action (MOA) for various 
adjuvants is not fully understood 232, and they react differently dependent on the antigen 
and host combination. It remains an arbitrary task to design a classification system for 
adjuvantsA, namely due to the unique immunogenic profiles 229. 
 
Adjuvants do not have a suitable comparator - or gold standard - for determining safety 
and efficacy 202, 233. The most effective method of establishing safety and efficacy profiles 
is to compare the adjuvanted vaccine with a non-adjuvanted and/or alternatively 
adjuvanted vaccine in a randomized, double-blind, human clinical trial 221. Adjuvant 
developers have yet to come across the Holy Grail – a universally applicable adjuvant that 
does not have any side effects. Even so, the benefits outweigh the risks and adjuvants have 
become an integral part to the vaccine R&D scene (Table 6.2). 
                                                          
A Attempts at categorizing include; origin of adjuvant, MOA, physiochemical properties, and administration 
route52 
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Chapter Seven: Recipe for success? 
 
Development of a New Generation Influenza Vaccines 
 
Abstract 
As infectious diseases cause approximately 25% of the annual global mortality, vaccines 
are found to be a time proven and promising response to infectious disease need. However, 
like for pharmaceutical small molecules, vaccine development is lengthy, risky and 
resource demanding. Faced with an attrition rate estimated around 80%, key opinion 
leaders were interviewed with the question: is there a recipe for success? 
 
Pronker, ES 
Claassen, E 
Osterhaus, ADME 
 
Vaccine (2012) 30: 51; 7344-7347   
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7.1 Introduction 
 
“It is better to prevent disease, than to allow avoidable human suffering 2.” 
 
The development of prophylactic vaccines targeting neglected viral infectious diseases is 
an unmet medical need within an international political setting. From the 57 million annual 
deaths worldwide, approximately 25% is attributable to infectious diseases. Of these 14.5 
million, at least 8% could have been prevented by childhood vaccination 33, 238. Although 
considerable progress has been made in the research and development (R&D) of vaccines, 
even now many existing, re-emerging and emerging infections do not have an efficient 
preventive moiety or vaccine.  
 
Vaccine development is a high risk and resource intensive multidisciplinary venture. 
Through an internationally regulated series of phases, a safe, effective, high quality and 
ethical vaccine is produced. This vaccine value chainA takes on average 10 years requiring 
an estimated investment of US$ 500 million 239. Nevertheless, developers are facing 
various obstacles leading to high project attrition rates  99. The success rate of a project is 
greatly enhanced by collaboration between the triple helix; knowledge 
institutes/universities, industry and regulatory and public health authorities (R-PHA). We 
interviewed key opinion leaders representing these arenas with the question: is there a 
recipe for success?  
 
7.2 Productivity Rates  
 
Vaccines are believed to be the most cost-effective medical intervention for mitigating 
influenza infections 94, 240. During a typical seasonal influenza outbreak, 5–20% of the 
population can be infected and a substantial number of patients stay at home for an average 
of 3–5 days. In financial terms, the annual burden in the United States of America alone is 
US$ 87 billion 241. In case of a pandemic, the financial ramifications would be far greater. 
By introducing an efficient public campaign, combining antiviral therapies and 
prophylactic vaccination, this socio-economic impact can be significantly reduced.  
 
Unfortunately, the vaccine industry is experiencing a so-called productivity gap 76. Since 
the last decade a trend has been observed that resources consumed during R&D do not 
result in the anticipated number of product launches 77. One aspect of this phenomenon is 
the success rate: the probability a candidate will successfully transition through the value 
chain phases 125. When taking pre-clinical development as a starting point, approximately 
6% of the vaccine candidates reach regulatory approval (Chapter 4). By comparison, inter-
pandemic influenza vaccines are considered lucrative, attaining an estimated 10% success 
rate (Chapter 4). 
 
                                                          
A  Value chain is internationally regulated phases a drug and vaccine have to complete before market entry. The 
chronological order of phases include: discovery phase, pre-clinical phase, human clinical trials phase I, II and 
III, regulatory approval by competent authorities, and market entry. After market entry some products need 
market surveillance and this phase is also known as clinical trial phase four. 
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This leaves the remaining 80% plus vaccine projects that will never reach the market. 
Initiatives may be discontinued at any point during the value chain, for any number of 
reasons 142, 220. From the perspective of the entrepreneur and investor, this can be a healthy 
decision when taken as early as possible. It is during the initial development stages that 
resources invested are still relatively low. Furthermore with every completed phase; the 
value of a project increases while the risk is reduced 242.  
 
7.3  Recipe for Success?  
 
In an attempt to understand the high levels of vaccine project attrition, we approached 27 
experts on their opinions of the topicA. 6 represent the knowledge institutions, 14 the 
industry and 7 are employed by the R-PHAs (Chapter 6). The interview transcripts were 
open-axial coded according to the grounded theory 218, resulting in a system analysis from 
we distilled the following four lessons for start-up companies. In random order:  
 
7.3.1 Plan Ahead  
 
Although seemingly a logical and cliché ingredient, experts claim it is undesirably taken 
for granted. By default, start-up companies focus on specific early phases in R&D, 
disregarding the perspective of the entire value chain. Key elements to take into 
consideration include project-team characteristics, and potential partnerships. The latter 
could guarantee clinical phase-3 entrance and huge investments in competition with ‘in 
house products’, further down the value chain.  
 
Starting with the composition of the project team; one has to take into account the natural 
setting in which vaccines are developed. The multidisciplinary character requires a flexible 
team of experienced professionals, capable of adapting to the dynamic nature of the 
project. According to the experts it takes the right combination optimistic individuals to 
overcome the obstacles, but also control and criticism (pessimists) leading to objective 
decisions on project continuation. Start-up companies have the tendency to develop an 
emotional bond with their project, clouding realistic judgment. Perhaps larger corporations 
are at an advantage in this respect. Vaccine candidates are “thrown over the wall” to other 
departments, facilitating these decisions throughout R&D.  
 
Second, planning ahead also pertains to considering collaborating with public and private 
stakeholders. According to the R-PHA representatives, the majority of start-up firms still 
seek regulatory advice and guidance too late. For example; scheduling the first 
consultation when planning to initiate human clinical trial phase I, yet returning from the 
meeting with protocol amendments for pre-clinical development. As a result, the 
experimental design has to be re-written and repeated, causing delays in the development 
time-line. Communication with the right stakeholders in the early stages of development 
greatly increases the chances of success.  
  
                                                          
A Interview tool available on request. Methodology and justification are described in: Chapter 6 
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7.3.2  Keep it Simple  
 
Most re-emerging and emerging infectious diseases are not eligible for traditional whole-
cell or live-attenuated inactivation strategies 176, 178. Vaccines targeting these pathogens 
require novel solutions, for example; sub-unit preparations in combination with an 
adjuvant for sufficient immunogenicity 52, 55, 243. Such radical innovations come at a price: 
developing vaccines with known correlates of protection (incremental innovations) 
significantly improves success rates and financial gains (Figure 7.1) 244.  
 
Figure 7.1 Risk profile for vaccine development, 
Comparing the development trends for vaccines targeting infectious disease with known correlated 
of protection, compared to unknown correlates of protection. The “all data” curve is labelled, yet 
labels apply to the other curves as well. Data is based on methodology as described in: (unpublished 
work) Pronker, ES. Weenen, TC. Commandeur, HR. Claassen, E. Osterhaus, ADME. September 
2011. Risk in vaccine R&D quantified: considerations for Investors. Paper presented at: The Fourth 
ESWI Influenza Conference, Malta.  
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Experts also relate this lesson to up-scaling of production. Most start-up companies are 
involved in the discovery phase up to human clinical trials phase I or II. In these stages 
relatively few dosages of the vaccine candidate are validated. However, as the candidate 
progresses through the value chain, the necessary amounts increase exponentially. By 
keeping production methods straight-forward, up-scaling and down-stream-processing of 
the vaccine is facilitated.  
 
7.3.3  Valuate Relevance  
 
Experts believe that start-up firms could reduce the chances of project attrition already at 
the start: selecting relevant target pathogens. Nevertheless, the notion of a ‘relevant target’ 
largely depends on the interpretation of the observer. It was understood from the 
interviews there are four pivotal arguments necessary when building a case to select the 
target. These include; disease burden, knowledge availability, technological feasibility and 
the business case (Table 7.1). The 27 key opinion leaders (KOLs) completed a weighted-
ranking exercise, in order to quantitatively indicate their point of view (Chapter 6).  
 
Table 7.1 Definition of motivators 
 
Motivator Definition 
Disease Burden 
In the case of vaccines for infectious diseases, such as pandemic 
influenza, the size of the market is unpredictable. Any argument relating 
to epidemiology or demographics of the market as a motivator to start a 
novel R&D programme. 
Knowledge 
Availability 
Preliminary knowledge based on experiments and existing knowledge 
on the workings of the immune system. Any argument relating to the 
(limits of) existing knowledge as a motivator to initiate a novel R&D 
programme. 
Technological 
Feasibility 
This refers to the state-of-the-art and niche market position of the 
(novel) technology. Any argument relating to the (limits of) existing 
state-of-the-art as a motivator to initiate a novel R&D programme. 
Business Case 
 Any argument relating to the business, strategy, investment 
opportunities or financial structures and frameworks that allow for the 
development of the drug, as a motivator to initiate a novel R&D 
programme. 
 
Similarities and differences between the opinions of the KOLs are highlighted in the 
matrix (Figure 7.2; Chapter 6). Both the knowledge institutes and R-PHA representatives 
consider the bur-den of disease the most persuasive argument. The societal benefit is 
believed to be the only justification for these KOLs to initiate a vaccine project. Industry 
representatives are (by default) more concerned with the business case when deciding on 
the relevance of a target pathogen. Although disease burden is in second place, the survival 
of the company drives the perception on the relevance of the target (i.e. incremental 
innovations secure steady markets from repeat business). With this knowledge, start-up 
companies can select more specifically which stakeholder to approach for collaboration but 
will have to compete with in-house-developed lead and target compounds.  
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Figure 7.2 Matrix showing perceptions of KOL on project motivators.  
The perspective of the knowledge institutes is taken as a reference. X-axis indicates motivators, 
listed in the ranking order of the knowledge institutes. Y-axis indicates ranking order of perceived 
importance; 1 indicates most important, and 4 least. Methods and justifications are described in: 
Chapter 6. 
 
 
 
7.3.4 Learn from Failure and Enjoy Success  
 
Last, but definitely not least: learning from failure. Sometimes, failing to overcome an 
obstacle is even necessary in order to proceed. Indeed, one successful vaccine is the sum of 
all previous discontinued projects. Moreover, none of the experts can recall a single 
vaccine project that was completed flawlessly. KOLs explain that it takes experience to 
identify rate-limiting factors, and to intervene when necessary. By definition start-ups have 
never failed before and therefore always need a truly vaccine experienced scientific and 
management team. Nevertheless, one should also be able to recognize a healthy project, 
and enjoy its success.  
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7.4  Conclusion  
 
As re-emerging and emerging infectious diseases persistently threaten public health, 
relentless dedication by all players in vaccine R&D is necessary. In order to continue to 
address unmet medical needs it is pivotal to change vaccine development attrition rates. 
However, improving the odds is challenging in the fragmented and multidimensional value 
chain. Moderating the risks for project discontinuation all boils down to recognizing the 
rate-limiting factors and taking appropriate action. Insights into potential obstacles are 
greatly improved by planning ahead, keeping R&D simple, and valuating the appropriate 
target pathogen, thereby steering away from radical innovations. Moreover, KOLS firmly 
believe start-up companies should not have to re-invent the wheel. As such, very early 
collaboration with experienced stake-holders can drastically improve success rates. 
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Chapter Eight: Summarizing Discussion  
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8.1 Innovation Paradox in Vaccine Target Selection 
 
When compared to NCE development, vaccine development is considered the most 
lucrative investment option within the scope of the biopharmaceutical industry 61. In terms 
of the amount of resources invested, subsequent return rates, compound annual growth 
rates, length of development timelines and risk: vaccines unequivocally outshine the 
performance of NCEs on all dimensions 60, 61.  
 
In essence, any activity aimed at developing a novel vaccine will generate a win-win 
situation for all involved. Prophylactic vaccines are unique in comparison to other 
therapies, in the view that the final product is acquired by national health authorities and 
the consumer segment consists of healthy individuals. From the perspective of the 
entrepreneur, manufacturer and investor; vaccines provide more value for every invested 
dollar when compared to that same dollar invested in an NCE 60, 61. From the standpoint of 
the health care institutes and regulatory agencies; disease prophylaxis is more cost-
effective than therapeutic symptom alleviation. Furthermore, appropriately directed 
vaccination campaigns are capable of eradicating an infectious pathogen from the face of 
the earth. An achievement valued highly by global society 49, 245.  
 
Additionally, the potential applications for vaccination are expanding. First generation 
prophylactic vaccine preparations generally targeted paediatric and adult infectious 
diseases. Nowadays, newer generation vaccines are being developed for 
immunotherapeutic applications 22. In light of the predicted biopharmaceutical industry 
trend towards personalized medicine, vaccine developers will inevitably be able to 
accommodate for this in the future. 
 
When focusing on prophylactic vaccines targeting human infectious diseases, novel 
vaccine development is subject to the process of valorization. Valorization is the act of 
creating added value to the vaccine candidate as it successfully progresses from one 
development phase to the next (Glossary 1.3.6)74. Generally, valorization in the health- and 
life-sciences sector starts with a specific unmet need, want or demand. Unmet entities 
appear in the following areas; target infectious pathogen, manufacturing technology, 
antigen delivery technology and immunostimulating excipients/active compounds for 
example (Figure 8.1) 80. As indicated in Chapter 2, it is dependent on the entrepreneurial 
style in which format the unmet medical entity will be addressed. The solutions are often 
sought after through realizing knowledge and/or technological inventions. In the case the 
solution consists of a vaccine candidate, it will have to complete the various stages of the 
value chain successfully before either the radical or incremental innovation may be 
awarded market entry. It is during the marketing-life cycle of the vaccine where its value 
and success are determined by the laws of supply and demand. Ultimately, vaccine 
accessibility determines whether the unmet entity has been adequately satisfied, at which 
point the valorization cycle repeats itself for another unmet medical entity 246. 
 
Nevertheless, over the past two decades the biopharmaceutical industry has been affected 
by a so-called innovation paradox. It delineates the situation whereby the amount of 
inventions do not reflect the predicted output, as measured by the quantity of successful 
market entries 74. This phenomenon has already manifested itself in the form of a 
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productivity gap, confirming that the increasing average investment in vaccine R&D 
activities far surpasses the anticipated product launches 99, 247. One can only start to 
imagine the consequences of such imbalance. For example; opting for risk-aversive 
strategies and selecting only incremental innovations for further development 244. 
 
Here we explore this innovation paradox, specifically focusing on vaccine target selection. 
The first section presents a brief theoretical overview on how needs, wants and demands 
are determined. The second section relates to how the unmet needs, wants and demands are 
addressed. The final sections describe the lessons learned and proposed future research 
topics. 
 
Figure 8.1 Valorization Cycle 
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8.1.1 Determining the Unmet Medical Entity 
 
Fundamentally; recognizing and identifying the unmet medical needs, wants or demands 
within the public health arena is influenced by the ruling scientific paradigm. A scientific 
paradigm is a theoretical frame-of-reference, universally acknowledged by the members of 
the scientific community, colouring all thoughts and practices within that period. It was a 
term first coined by historian Thomas Kuhn in 1962 248, who observed that the evolution of 
knowledge and inventions occurs in cyclical episodes. As described in The Structure of 
Scientific Revolutions, a cycle involves periods of so-called normal science and 
revolution248. It is the latter which results in a paradigm shift; a period capable of altering 
the common discourse within the subsequent era of normal science. 
 
A scientific paradigm is reflected in the technological and intellectual innovations within 
that particular normal or revolutionary cycle. Although discrepancies remain on 
specifically delineating scientific paradigm boundaries, the current state of the art - since 
the 1980s - is said to belong to the information-age 249-252. In other words, technological 
and intellectual evolution is influenced by the discourse of that particular scientific 
paradigm. Furthermore, technological and intellectual innovations transition according to 
theories of industry and product life-cycles 253. These are characterized by periods of 
expansion, stagnation and recession, where expansion is believed to be triggered by radical 
innovations or significant historical events 253, 254. Even though only one scientific 
paradigm dominates, both industry and product life-cycles influence public life 255. 
 
Given the present economic climate, it is believed we are currently experiencing a shift 
into a new cycle where efficiency and sustainability are considered the leading emotion 256. 
Such a scientific paradigm shift already has repercussions on industry activities and related 
strategic decisions. For example, the biopharmaceutical industry is adopting strategies for 
prolonging company survival. Topics at the organizational-level of vaccine project 
development - such as the predictability of research and development (R&D) productivity 
and successful portfolio management outcomes - have become popular subjects of debate. 
Moreover, there is a shift from focusing on increasing the output of the vaccine value 
chain, to a combination of; maximizing the benefit of the output, reducing the input and 
increasing efficiency of the system. Additionally; the earlier along the value chain the 
decision on project discontinuation takes place, the more beneficial to society as a 
whole257. 
 
Where does this leave vaccine target selection? As published by Buchanan et al (2011); 
“depending on what is created, innovation (or lack of) can worsen existing injustices or 
create new injustices, or it can lessen existing injustices 30.” In view of the strong 
correlation between health and wealth 3, certain infectious pathogens are known as 
poverty-inducers, thereby highlighting the necessity for selecting appropriate target 
pathogen for vaccine development. In short, while the interpretation of the (re-) emerging 
and neglected diseases is dependent on the current scientific paradigm, the technological 
and intellectual state-of-the-art influences whether the unmet entity can and/or will be 
addressed. 
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8.1.2  Addressing the Unmet Medical Entity 
 
The desired outcome of valorization is realizing a public health unmet need, want or 
demand. Whether innovation materializes as an action or a reaction to the unmet entity is 
beyond the scope of this dissertation. Nevertheless, we ask ourselves if valorization is 
capable of commercializing an appropriate innovative response to address the unmet 
medical entity. 
 
When it comes to addressing the unmet entity, there is a distinction between the level at 
which the unmet medical entity is manifested, and the level at which valorization takes 
place. The relationship between the micro-level responses to macro-level issues is best 
understood using a philosophical causal-mechanism based explanation. A mechanism is 
generally defined in terms of both the effect produced, as well as the entities of a causal 
process that result in the effect of interest 258. It is best visualized using Coleman’s bathtub 
framework (Figure 8.2)259. 
 
Coleman’s model illustrates the underlying analysis required for finding the causal 
mechanisms that lead to the desired macro-level phenomenon. It is believed that simply 
associating macro-phenomena with each other is insufficient (Arrow 1). Therefore an 
analysis of the so-called black-box is essential in order to understand the collective 
dynamics and interpret the micro-level and macro-level action-reaction reciprocity.  
 
Figure 8.2 Coleman’s bathtub and placement of chapters, adapted from 258 
Actor* indicates established organizations, start-up firms and entrepreneurs. 
 
 
 87 
Actions at the micro-level generate both intended and unintended social outcomes at the 
macro-level 258. This notion relates back to the philosophical principal of action. According 
to mechanism-based theories, an individual’s action is primarily oriented as a reaction. 
Similarly, at the organizational-level, a firm’s strategy is determined by the industry 
landscape within which it operates. However, actions are channelled by the structures 
surrounding the actor, influencing both motives driving the activity as well as shaping the 
anticipated outcome. Hence, the full impact of an actor’s intended outcome can only be 
assessed by studying those structural elements. This consists of holistically evaluating the 
stages including the situational (Arrow 2A), action-formation (Arrow 2B), and 
transformational (Arrow 2C) mechanisms 258. 
 
Given the interconnectedness of modern society, realizing prophylactic vaccines targeting 
infectious diseases generally affects the global community at the macro level. One unique 
feature of infectious diseases is their ability for transmission between humans. Taking 
ceteris paribus, healthy individuals have an equal chance of coming into contact with the 
natural pathogen and developing the infection. Although the reservoir for many infectious 
pathogens is unknown, the most efficient carrier is the (asymptomatic) infected individual.  
Human carriers allow for both epidemic and endemic infectious diseases to circulate 
within and between communities. As a result, realizing vaccine innovations reduces 
infection transmission, thereby inherently affecting the global population. 
 
In the majority of cases, the answer to the public health unmet medical entity is provided 
by the private-sector. The response to the unmet medical entity is generally formed by 
vaccine industry and by entrepreneurs in start-up companies. With these actors 
representing micro-level activity, the individual research chapters in this dissertation cover 
specific segments of the black-box.  
 
8.1.2.1 Situational Mechanism 
 
Both Chapter 2 and 7 describe the situational mechanisms shaping entrepreneur and firm 
action. To start off with, the theory-extending Chapter 2 delineates the entrepreneurial 
contributions towards science-based venturing in vaccine R&D. According to Bracker et al 
(1982), three entrepreneurial typologies can be distinguished based on motivation and 
management styles 260. These include the situational entrepreneur, the craftsman and the 
opportunistic entrepreneur 260. By applying this framework to the context of valorization, it 
is evident the three styles inherently possess specific competences that are - logically - 
most effective at different stages of the value chain. Generally the entrepreneur should be 
able to recognize the opportune moments to enter, and exit, the vaccine value chain. It is 
during this window of opportunity the entrepreneur can contribute most effectively; on the 
one hand benefitting from relative low-entry costs, while on the other potentially 
maximizing returns. 
 
Typically, during the initial start-up phases of a given vaccine candidate, the target disease 
selection is unrestricted. In fact, a former public health key opinion leader rationalized that 
at any point in time, research is ongoing on all of the known pathogens. Unfortunately, one 
of the situational mechanisms is attributed to the perception of risk. Translating 
fundamental research into a viable product - more often than not - leads to project 
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discontinuation. This is partially due to the unclear commercial potential of the novel 
vaccine candidate during these earliest stages of development. Particularly right after 
completing the pre-clinical development phase and before the vaccine candidate moves to 
the first-in-human clinical trials, it is challenging to attract investors and maintain a 
positive cash-flow. This infamous bottleneck can best be described as a tipping-point, most 
often colloquially referred to as the ‘valley of death’261.  
 
Bridging the valley necessitates the adoption of the most effective risk- and project-
management strategies for the evaluation of project viability. Chapter 7 complements 
Chapter 2 by offering insights into several strategies that could increase the likelihood of 
building successful ventures. Essentially this research chapter is aimed at entrepreneurs 
and start-up firms. It ameliorates four recipes to be taken into consideration prior to 
initiating a vaccine R&D project, including; planning ahead, keeping it simple, valuating 
relevance and learning from failure. Such recommendations will hopefully be extended 
into business practices, finding leverage within the current scientific paradigm. 
 
8.1.2.2 Action-Formation Mechanism 
 
The vaccine value-chain defines the action-formation mechanism. It describes the 
necessary chronological phases required to develop a product innovation up to the point of 
market entry. Both Chapters 5 and 6 identify conditions that could influence the general 
productivity of the value chain. Chapter 5 accounts for the timelines in clinical data 
management whereas Chapter 6 provides an overview of the potentially rate-limiting 
factors encountered throughout the value chain. Although the challenges do not relate 
directly to vaccine target selection, in essence; any reason for project delay or 
discontinuation does affect the end-goal of attaining public health unmet entities. 
Nevertheless, it is clear that action-formation mechanisms are an under-developed area and 
could benefit from further research. 
 
In the face of the first-time-right principal and associated development time pressure, 
Chapter 5 contributes by researching data management efficiency in human clinical trial 
procedures. Although this is not a direct measure for organizational dynamics, data 
management systems are essential for compiling a dossier and have the potential to 
significantly impact value chain timelines. Focusing on a Clinical Phase I as executed by 
an academic research organization, it is believed the results are directly applicable in other 
clinical trial settings. Currently, 100% of the data points are subjected to intense 
examination by at least four independent institutions 262. It is believed that selecting critical 
data points in advance will significantly reduce the amount of time spent validating and 
cross-referencing them during later stages of development. This chapter proposes a novel 
framework supporting an evidence-based approach; a number-needed-to-treat resiliency 
model for selecting critical data points that are directly related to the clinical endpoints. By 
pre-selecting data points eligible for sponsor queries prior to the start of the clinical study, 
the effect could lead to exponential time-conservation throughout clinical-experiment 
phase of the value chain. When taking into account all clinical trials around the world, 
implementing such a strategy could translate into potentially saving billions in financial 
resources. 
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Chapter 6 endeavours to uncover additional rate-limiting factors affecting adjuvanted-
vaccine R&D. Although this topic is covered in the literature, a method with which to 
compare the rate-limiting factors with each other is lacking. Opting for a qualitative 
approach, 27 key opinion leaders were approached representing the knowledge institutes, 
industry and regulatory/public health authorities (R/PHA). Each expert within the field of 
adjuvanted-vaccines was interviewed on how they perceive the magnitude of the rate-
limiting capacity of the factors. In essence, the interviews were designed to capture the 
self-interest component as supported by the principal-agent theory (PAT). The opinions 
were quantified using an effective weighted-ranking technique in order to indicate the top-
ten rate-limiting factors. Subsequently the perceptions on the rate-limiting factors are 
plotted in a matrix-configuration, to visualize the differences in opinion. Analysis into the 
interview transcripts reveals four reasons underlying this difference, namely; risk 
management, innovation strategy, valuation and funding.  
 
One of the more significant observations from Chapter 6 is the supply-driven value chain 
configuration. Based on PAT, the relationship between the three expert groups is 
diagnosed with a partial agency-problem. Partial in the sense that there are conflicting 
interests between the internal preferences of each of the three groups, yet novel 
adjuvanted-vaccines have recently been awarded market authorization. Nevertheless, the 
agency-problem leads to more stringent risk management strategies. This is reflected by 
the choice in the target disease areas currently in the development pipeline, which favours 
me-too markets 224.  
 
Solutions to agency problems are generally the following: monitoring to evaluate 
information symmetry, alignment of interests and bureaucracy 198,199. A proposed solution 
to the conflicting interests is found by converting the value-chain into a demand-driven 
configuration, thereby essentially aligning interests (Figure 8.3). Ideally in the demand-
driven state the unmet medical entity (e.g. epidemiological data) is added to the system and 
will be regarded as the principal. Consequently, the information asymmetry existing 
between the knowledge institutes, industry and R/PHA will also be reduced. The three 
agents would interact in order to satisfy the common goal as set by the principal. In this 
case, it would be meeting an unmet medical entity. This, however, should not interfere 
with the original purpose of each of the agents; the knowledge institutes would carry on 
conducting fundamental research, the industry would remain profit-seeking entities, and 
the R/PHA would continue to regulate and monitor the safety, efficacy, quality and ethical 
parameters of value chain procedures. Ultimately, such an approach could result in 
broadening the portfolio of targets selected for vaccine development. 
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Figure 8.3 Demand-driven value chain configuration 
The unmet medical entity is considered the principal, and the knowledge institutes, 
Regulatory/Public Health Authorities and Industry are considered the agents. 
 
 
 
8.1.2.3 Transformational Mechanism 
 
In this dissertation, both Chapters 3 and 4 provide tools for calculating the productivity of 
organizational activity. Data on successful market entry is used as a measure of 
productivity, which in turn is used to indicate the efficiency of the transformational 
mechanism. Nevertheless, being awarded market authorization is only the first step. In 
order to fully comprehend the transformational mechanism, the impact of vaccine 
accessibility in local communities should also be taken into account. This latter aspect falls 
beyond the scope of the research in this dissertation, yet is covered by the access 
framework as published by Frost et al (2004) 263. 
 
To start off with, Chapter 3 reviews the literature on organizational productivity. Seven 
publications were identified, reporting market entry success rates reflecting the 
productivity of the new chemical entity (NCE) value chain. Productivity rates are taken as 
the ratio between the input and output of the value chain. The results range wildly from 7% 
to 78%. Further analysis reveals that the methodologies differ along the dimensions of data 
set in- and exclusion criteria as well as the consideration of the in- and dependent 
variables. Although the data are said to express the same measure of productivity, clearly a 
standardized calculating protocol is lacking. Nevertheless, such calculations ultimately 
confirm the existence of the productivity gap, even if a consensus is lacking regarding the 
severity of the paradox. 
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In the majority of publications it is unclear whether vaccines have been incorporated in the 
datasets. Only one article from 1996 explicitly focused on vaccine development success 
rates, calculating a probability of 22% 264. Chapter 4 can be seen as an extension of the 
previous chapter, by defining the organizational-level productivity to fit vaccine 
development specifically. For the purpose of this dissertation, productivity is defined by 
the cumulative rate of vaccine candidates successfully transition from the pre-clinical 
phase up to the point of market registration. Without the intension of forecasting a trend, 
our dataset implicates a success rate of 6%. This indicates a substantial productivity gap in 
the value chain, tailored exclusively for vaccine candidates.  
 
If this crude statistic is to be compared to the NCE productivity rate as published by 
Dimasi (2003), perhaps investors might hesitate before investing in vaccine 
development110. Nevertheless, investors seeking strategic financial advice should take 
additional confounding variables into consideration, adding extra dimensions to the 
concept of productivity. For example, stratifying data into chronological value chain 
phases and disease areas. This allows for highlighting common developmental 
opportunities - as well as the bottlenecks - shared by vaccine candidates within specific 
disease areas. Additionally, the average vaccine requires only half the total investment that 
it would take a NCE to reach the status of market registration. This implies that the 
financial risk for investing in vaccine development is less when compared to that of 
NCEs242. 
 
8.1.3 Final Thoughts and Implications 
 
The productivity gap is often viewed as an unfortunate symptom of an inefficient vaccine 
development system. Some research groups support the notion that the productivity gap is 
a consequence of the value chain itself. They argue that the classical, linear value chain can 
benefit from being restructured 265. Solutions proposed include an iterative proof-of-
concept phase 266, 267, question-based drug design 64 and prototypical drug development 268. 
Other groups believe that the productivity gap is a consequence of the unknown, 
confounding factor. For example the target disease area; vaccine developers are believed to 
have exhausted the list of relatively easy disease targets - the so-called ‘low-hanging-
fruits’. Consequently, the remaining targets are considered relatively more complex, which 
translates into higher attrition rates 269, 270. 
 
To our knowledge, we believe that the origin of the innovation paradox in vaccine target 
selection cannot be traced back to one single cause. The paradox can only be fully 
comprehended once the entire valorization cycle - of which the vaccine value chain 
represents one component - is taken into consideration. In other words, one would not 
work from a linear value chain but rather from an all-inclusive cycle. Such an overview 
allows for holistically examining the innovation paradox from a multidisciplinary 
perspective, making it possible to identify several causes that contribute to the productivity 
gap. 
 
The valorization cycle delineates a number of sequential steps in the transfer of technology 
from the symbolic ‘bench to bedside’ and back again, while simultaneously accumulating 
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value (Figure 8.4). All ten steps are considered equally important, reinforcing each other as 
the vaccine candidate transitions from one to the next. If one of the steps were to be 
eliminated or skipped, it would naturally follow that the cycle disintegrates and the vaccine 
is arrested in that stage of development. Moreover, the cycle is sub-divided into three 
distinct segments, based on the discourse dominating that particular valorization aspect. 
These include the scientific, economic and market and policy discourse. Although each of 
the steps within a segment inherently possesses attributes that could lead to project 
discontinuation, the innovation paradox manifests itself at the interface between segments. 
 
For the sake of illustrating the rationale, valorization starts at the idea stage (Step 1). In the 
case of high-tech vaccine development, this idea would most likely originate within the 
scientific discourse. The invention - whether it is technological or knowledge based - 
should motivate the individual to take empirical action (Step 2a and b). Nevertheless, the 
type of activity required to evaluate an idea is inevitably shaped by the situational 
mechanisms, and the individual’s entrepreneurial style 242. Once the invention has been 
favourably assessed in terms of its feasibility and viability, it will eventually materialize 
into a patent, publication, report or product (Step 3).  
 
It is at the intersection between the realization (Step 3) and the proof-of-concept stages 
(Step 4) where the dominant discourse changes. Whereas the previous three steps focus on 
developing the scientific aspect, the discourse in the fourth step is oriented towards 
economic and commercial disciplines. It is at this point in the cycle that the inventor starts 
negotiating with another, more profit-seeking culture of investors and related stakeholders. 
This barrier should not be confused with the valley of death, which takes place after the 
pre-clinical development (Figure 8.4; between step 4 and 5). In the case of the first-time 
start-up firm, spin-off company or entrepreneur, having to learn this completely new 
dialogue represents a certain level of commitment. Similarly in an established firm, the 
invention would be translated by a scientific liaison officer to a more senior management 
level.  
 
In both scenarios the value of the invention has to be translated from one discourse into the 
next. If the message is misunderstood by the receiver, the process loops back to the 
metaphorical drawing board. This loop is also referred to as the Dutch innovation paradox. 
In short; while research institutes in the Netherlands rank sixth place in the global 
innovation index of 2012 271, somehow commercialization of the invention scores low-to-
mediocre when compared to the performance of other countries 272. Several key opinion 
leaders affirmed that at this interface there is no way of knowing the outcome of a 
decision. The one invention that is discontinued might have turned out to be life-saving, 
whereas the one that is selected to proceed still has a chance of getting discontinued along 
any of the subsequent steps (Step 4; proof-of-concept, Step 5; evaluation and Step 6; up 
scaling) 273. Perhaps the difference in discourse partially accounts for the inefficiency in 
overcoming the Dutch innovation paradox.  
 
The second segment - describing the action-formation mechanism - is dominated by 
economically oriented discourse. As elaborated by Chapters 5 and 6, this portion of the 
valorization cycle holds numerous rate-limiting elements. Essentially, this is when the 
vaccine candidate undergoes a series of rigorous experiments. Not only does this filter 
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remove the weaker candidates, it simultaneously reinforces and strengthens the value of 
the successful vaccine candidate. The crude measure on productivity - in terms of absolute 
market entries (Chapter 3 and 4) - merely establishes the efficiency of this economic 
segment. 
 
Ultimately the success of a vaccine is influenced by its introgression into the market (Step 
7). At this intersection it is believed the innovation paradox is less dependent on the 
communication barriers between the two segments. One of the reasons is that fact that 
economic activities are naturally directed towards market entry, and are therefore better 
informed on market and policy discourse. It is the accessibility that contributes to the 
innovation paradox. The framework as published by Frost et al (2004), and later elaborated 
on by Morel et al (2005), describes this bottleneck in terms of accessibility, availability, 
affordability and architecture 263, 274.  
 
The third section of the valorization cycle essentially focuses on the transformational 
mechanism. Once the vaccine has been awarded market authorization, and is accessible to 
the target population, the dynamics of the market landscape changes (Steps 8 and 9). Such 
changes necessitate continuous evaluation of the market, and this information feeds into 
the perception of the (un-)met medical entity (Step 10).  
 
Interpreting the unmet medical issue is influenced by the scientific paradigm in which the 
market and policy discourse exists and agenda setting as well. According to the agenda 
setting theory by McCombs et al (1972); the ranking of issues is dependent on the source 
of the information, which in turn influences the perception of reality 275. Demand 
articulation is therefore influenced by the somewhat hidden agendas of the media, public, 
commercial and policy spheres.  
 
Since we consider valorization as a cyclical process; any met issue ultimately reveals 
another unmet one. Schmidt et al (2007) rationalizes that there are an infinite number of 
unmet problems 276. Unfortunately there are physically insufficient resources available to 
address all unmet issues, given the current vaccine value chain and development 
practices276. Such arguments emphasize the need for interpreting the unmet issue 
appropriately in order to allocate resources as efficiently as possible. Ultimately, from the 
pool of unmet entities, only a few will be articulated. 
 
The final contributor to the innovation paradox materializes at between the demand 
articulation (Step 10) and idea generation (Step 1). This is where the valorization cycle 
comes full circle, and where the third and last discourse boundary has to be crossed. This 
communication barrier between the market and policy discourse and the scientific 
discourse is influenced by supply-driven principal-agent relationships (Chapter 6). The 
agents select the unmet medical issues based on their internal preferences, most commonly 
through incrementally building on previous innovations. In this current system, unmet 
problems ARE being addressed; however it is a question of whether this response truly 
corresponds to the unmet medical needs at the societal-level. One proposed solution is the 
demand-driven value chain configuration, which allows for the agents to act directly on the 
unmet issue from the epidemiological source. 
  
  
Fi
gu
re
 8
.4
 
V
al
or
iz
at
io
n 
Te
ch
no
lo
gy
 T
ra
ns
fe
r 
C
yc
le
, a
da
pt
ed
 fr
om
 C
la
as
se
n 
(2
00
8)
.  
Th
e 
gr
ey
 a
re
as
 in
di
ca
te
 th
e 
do
m
in
an
t d
isc
ou
rs
e 
w
ith
in
 th
e 
re
sp
ec
tiv
e 
va
lo
riz
at
io
n 
st
ep
s 
* 
 
Fr
os
t a
nd
 R
ei
ch
 (2
00
4)
 a
cc
es
s f
ra
m
ew
or
k 
26
3  
**
  
M
cC
om
bs
 (1
97
2)
 th
eo
ry
 o
n 
ag
en
da
 se
tti
ng
 27
5   
 
1.
 Id
ea
2a
. F
ea
si
bi
lit
y
2b
. V
ia
bi
lit
y
3.
 R
ea
liz
at
io
n
4.
 P
ro
of
-o
f-
co
nc
ep
t
5.
 E
va
lu
at
io
n
6.
 U
ps
ca
lin
g
7.
 In
tro
gr
es
si
on
 in
to
 M
ar
ke
t
8.
 C
lie
nt
 a
nd
 C
on
su
m
er
 
Fe
ed
ba
ck
9.
 U
nm
et
 M
ed
ic
al
 E
nt
ity
10
. D
em
an
d 
A
rti
cu
la
tio
n
Su
pp
ly
-d
ri
ve
n 
V
al
ue
 C
ha
in
x
Pa
te
nt
x
Pu
bl
ic
at
io
n
x
R
ep
or
t
x
Pr
od
uc
t
A
cc
es
s F
ra
m
ew
or
k
x
A
cc
es
si
bi
lit
y
x
A
va
ila
bi
lit
y
x
A
ff
or
da
bi
lit
y
x
A
rc
hi
te
ct
ur
e
M
ed
ic
al
 S
ci
en
ce
 L
ia
is
on
Consumer Perception and 
Acceptance
x
(C
lin
ic
al
) S
af
et
y
x
(C
lin
ic
al
) E
ff
ic
ac
y
x
Q
ua
lit
y
x
Le
gi
sl
at
ur
e
x
Ec
ol
og
ic
al
 Im
pa
ct
Em
pi
ri
ca
l C
yc
le
Va
lle
y-
of
-D
ea
th
A
ge
nd
a 
Se
tt
in
g
x
M
ed
ia
x
Pu
bl
ic
x
C
om
m
er
ci
al
x
Po
lic
y
Sc
ie
nt
ifi
c 
Pa
ra
di
gm
D
ut
ch
 In
no
va
tio
n 
Pa
ra
do
x
M
ar
ke
t a
nd
 P
ol
ic
y 
D
is
co
ur
se
E
co
no
m
ic
 D
is
co
ur
se
Sc
ie
nt
ifi
c 
D
is
co
ur
se
94 
 95 
Lessons Learned 
 
The Innovation Paradox in vaccine target selection is best viewed using a holistic, multi-
disciplinary perspective. There is not one single cause that can be identified as the main 
instigator to the productivity gap. By taking the whole cycle into account there are 
numerous bottlenecks that affect productivity. These include the medical science liaison, 
access framework and supply-driven value chain.  
 
Technology transfer is essential in the valorization process of innovations. Only through 
proper guidance will the inventor be able to overcome the economic discourse barrier and 
have a shot at commercializing the invention. Effective communication regarding both the 
specifics of the invention, and value is decisive at this interface. 
 
Clinical data management can benefit from a number-needed-to-treat resiliency model to 
identify high-risk data points. Pre-selecting data points that are critical to the 
understanding of statistical outcome of the clinical trial is considered more efficient than 
the current 100% verification by several independent institutions. This would significantly 
save resources and reduce development timelines. 
 
Weighted ranking is an effective tool for converting qualitative information into 
quantitative data. Moreover it supports the principal agent theory in terms of capturing the 
self-interest component of the principal and agents, while simultaneously visualizing the 
results using a matrix-model. Weighted-ranking is a widely used tool within the social 
sciences, yet this manuscript demonstrates its function within the economic and 
management research disciplines as well.  
 
Risk profiles are useful tools when it comes to illustrating and evaluating the productivity 
of vaccine and NCE development. Productivity is defined as the output generated by the 
input. The risk profiles combine the transition probability of a vaccine or NCE candidate 
from one value chain phase to the next, with either; the investment required for that 
particular phase, or the duration a candidate remains in that particular development phase. 
Visualizing such data in a graphical form provides an overview of the value chain 
procedures and allows for identifying common bottlenecks. Moreover it allows for 
investigating the impact of numerous other variables and their effect on the risk profile. 
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Suggestions for Further Research 
 
The innovation paradox in vaccine target selection could benefit from research covering 
the medical science liaison gap and evading the Dutch Knowledge Paradox trap. 
According to recent meta-analysis by Evanschitzky, et al (2012), new product success 
factors include; product, strategy, process, marketplace and organization 277, 278. Especially 
during the fuzzy front-end stages; enhancing the effectiveness of valorization technology 
transfer activities can be seen as one of the main strategies that could contribute to 
reducing the productivity gap. One of the proposed research topics includes the difference 
in discourse between the realization and proof-of-concept steps, is communicating the 
potential value of the patent, publication, report and/or product.  
 
A second proposed research topic would entail the transformational-mechanism, focusing 
specifically on the accessibility of vaccines and the diffusion of knowledge and technology 
in both high-income economies (HIE) and low-to-medium income economies (LMIE). 
Currently vaccine manufacturing landscape is an oligopoly, whereby vaccine development 
expertise is concentrated within five multinational biopharmaceutical companies from 
high-income economies (HIE). Intensified merger and acquisition activities 279, as well as 
substantial barriers for start-up firms entering this high-tech industry, are examples that 
contribute to a reduction in the number of players, thereby reinforcing the oligopoly. 
Consequently, a handful of companies influence the portfolio of disease targets available 
to first-time vaccine developers. In terms of vaccine accessibility; once the vaccine is 
manufactured - generally by HIE vaccine manufacturers - there is an average lag-period of 
15 to 20 years between the initial market introduction of a vaccine in the private market 
(usually HIE) to the final general-use and public market access phase (usually 
LMIEs)280,281. When taking vaccines targeting Haemophilus Influenzae Type B as a case 
study; vaccine manufacturers in LMIEs are also capable of delivering a substantial 
quantity of dosages, thereby reducing the lag period substantially. Nevertheless, few 
studies analyze the vaccine market based on diffusion of innovation and technology 
theories. In the view of the changing vaccine manufacturing landscape, this presents a 
critical area for further analysis. 
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Samenvatting 
 
De volksgezondheid wordt continu op de proef gesteld door nieuwe en terugkerende 
infectie ziekten. Een bijkomend groeiend probleem is de resistentie van pathogenen tegen 
de beschikbare behandelingen, waaronder vaccins. Deze aanhoudende en bedreigende 
onvervulde medische behoefte daagt vaccin ontwikkelaars uit om in te spelen op 
toekomstige epidemieën. Er zijn echter onvoldoende middelen beschikbaar om alle 
onbeantwoorde medische vraagstukken aan te pakken. Zo duurt de ontwikkeling van het 
gemiddelde vaccin van ‘bench to bedside’ ongeveer 10 jaar, en lopen de kosten op tot meer 
dan € 400 miljoen. Vaccinontwikkeling wordt bovendien beïnvloed door de zogenaamde 
innovatieparadox: het aantal innovaties groeit terwijl de te verwachten uitkomst - 
voldoende succesvolle gecommercialiseerde producten - achterwege blijft. Deze situatie is 
gedurende de afgelopen jaren steeds duidelijker naar voren gekomen en heeft een 
significante invloed op de productiviteit van vaccine valorisatie, die hierdoor achterblijft. 
Gezien het positieve verband tussen volksgezondheid en welvaart, is het van cruciaal 
belang om het juiste ziektegebied te selecteren voor vaccine ontwikkeling. 
 
Dit proefschrift bespreekt deze innovatieparadox in het kader van de selectie van 
menselijke infectieziekten voor de ontwikkeling van vaccins. Als het gaat om 
selectiecriteria van de desbetreffende infectieziekte, kan er een onderscheidt gemaakt 
worden tussen het niveau waarop de besmettelijke ziekte zich manifesteert 
(maatschappelijk-niveau), en waar valorisatie plaatsvindt (ondernemerschaps-, en 
organisatorisch-niveau). De actie-reactie wisselwerking tussen deze macro- en micro-
niveaus ligt in het hart van de innovatieparadox. De zes hoofdstukken onderzoeken vaccin 
valorisatie vanuit het standpunt van de ondernemer en de organisatie. De nadruk wordt 
gelegd op strategieën die potentieel het selectie proces stimuleren of beperken. Daarnaast 
stellen wij dat het valorisatie proces doelmatiger wordt als het een allesomvattende cyclus 
is. Zo worden er een aantal opeenvolgende stappen voorgesteld die het proces van bench-
to-bedside en weer terug begeleiden. Hierdoor wordt de onvervulde medische behoefte 
nauwkeuriger gedefinieerd en kan er een accurate inschatting gemaakt worden van de 
benodigde middelen en de manier van aanpak. Evengoed is het aan de biofarmaceutische 
gemeenschap om in de opeenvolgende stappen zijn innovatiekracht te blijven tonen en 
daarmee veilige en effectieve vaccins te ontwikkelen ten behoeve van de volksgezondheid. 
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Summary 
 
Public health is continually threatened by re-emerging and newly emerging infections, as 
well as pathogen resistance to available intervention strategies, including vaccines. This 
persistent threat of the unmet medical need challenges vaccine developers to anticipate 
future epidemiological outbreaks. Nevertheless, there are insufficient resources available to 
address all unmet medical needs:  developing the average vaccine candidate from the 
symbolic ‘bench to bedside’ takes approximately 10 years requiring an investment 
exceeding €400 million. Furthermore, vaccine development is affected by the so-called 
innovation paradox. In short; regardless of increasing research and development activities, 
the predicted output - as measured by successful market entry of the commercialized 
product - is lacking behind. This situation has intensified over the past few decades and 
significantly impacts the productivity gap in vaccine valorization. In the view that there is 
a correlation between health and wealth; it is critical to select the appropriate target disease 
area for vaccine development.  
 
This dissertation evaluates the innovation paradox in selecting human infectious disease 
targets for vaccine development. When it comes to selecting the target, there is a 
distinction between the level at which the infectious disease is manifested (societal-level), 
and the level at which valorization takes place (entrepreneurial- and organizational-level). 
This action-reaction reciprocity between the micro- and macro-level lies at the heart of the 
innovation paradox. The six research chapters offer an assessment into entrepreneurial- 
and organizational-level productivity, focusing on strategies that would potentially 
stimulate and restrict vaccine target selection. Additionally, we propose the valorization 
process would be more efficient as an all-inclusive cycle, delineating a number of 
sequential steps from bench-to-bedside and back again. Such a cycle would allow for 
proper assessment into the available resources, in order to most accurately determine and 
address the unmet medical need. Nevertheless, it is up to the biopharmaceutical 
community to demonstrate their innovative capacity within the context of valorization in 
order to continue to develop safe and effective vaccines for the benefit of public health. 
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Public health is continually threatened by re-emerging and newly emerging infections,
as well as pathogen resistance to available intervention strategies. This persistent threat
challenges vaccine developers to anticipate future epidemiological outbreaks.
Nevertheless, there are insufficient resources available to address all unmet medical needs.
Furthermore, vaccine development is affected by the so-called innovation paradox,
significantly affecting vaccine valorization productivity. In the view that there is a
correlation between health and wealth; it is critical to select the appropriate target
disease area for vaccine development. 
This dissertation evaluates the innovation paradox in vaccine target selection. When it
comes to selecting the target; infectious diseases are manifested at the macro-level, for
which valorization solutions are pursued at the micro-levels. This micro- and macro-level
action-reaction dynamic lies at the heart of the innovation paradox. The six research
chapters offer an assessment into entrepreneurial and organizational micro-level
productivity, focusing on strategies that stimulate or restrict vaccine target selection.
Additionally, we propose the valorization process would be more efficient as an all-
inclusive cycle, delineating a number of sequential steps from bench-to-bedside and back
again. Such a cycle would allow for proper assessment into the available resources, in
order to most accurately determine and address the unmet medical need. 
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